Natural Agents for Preventing Skin Damage Induced by Visible Light: A Systematic Review of Preclinical and Clinical Evidence Authors: Azahara Rodríguez‐Luna, Alicia Zamarrón, Cristina García‐Muñoz, Juan‐Carlos Hernández‐Rodríguez, Henry W Lim, Salvador González Published: 2026 ABSTRACT ABSTRACTBackground/PurposeVisible light (VL), and particularly high‐energy visible light (HEVL), reaching Earth's surface has emerged as a relevant contributor to skin damage. VL has been implicated in oxidative stress, inflammation, pigmentation disorders, and photoaging, especially in individuals with darker skin phototypes. As conventional sunscreens offer limited protection in the visible spectrum, increasing attention has been directed toward complementary photoprotective strategies, including the use of natural compounds with antioxidant and anti‐inflammatory properties. This systematic review aims to evaluate and synthesize the available preclinical and clinical evidence on the photoprotective effects of natural compounds against VL‐induced skin damage, emphasizing their mechanisms of action, efficacy, and safety.MethodsA comprehensive literature search was performed to identify studies reporting validated objective outcomes, including colorimetric parameters, diffuse reflectance spectroscopy, or clinical grading scales. Eligible studies were included, qualitatively synthesized, and risk of bias was evaluated.ResultsPreclinical studies demonstrated that natural compounds mitigated VL‐induced oxidative stress, inflammation, and pigmentation‐related pathways. Clinical studies showed that formulations containing natural compounds improved VL‐induced erythema and pigmentation outcomes. However, considerable heterogeneity was observed in irradiation protocols, outcome measures, and study designs, precluding quantitative meta‐analysis.ConclusionOverall, available evidence supports a protective role for selected natural compounds against VL‐induced skin damage, particularly through antioxidant and anti‐inflammatory mechanisms, with the strongest clinical evidence focusing on natural sources of polyphenols. Nevertheless, this review highlights the need for standardized phototesting protocols and well‐designed clinical trials. Future research should focus on comparative efficacy, long‐term safety, and integration of natural compounds into combined photoprotection strategies tailored to different skin phototypes.Keywords: high‐energy visible light, natural compounds, photoaging, photoprotection, pigmentation, skin photobiology, systematic review, visible lightantioxidants Introduction Visible light (VL, 400–700 nm) accounts for approximately 50% of solar radiation that reaches the Earth's surface and represents the only portion of the electromagnetic spectrum perceptible to the human eye. Beyond natural solar exposure, the “digital age” has introduced chronic contact with artificial light sources, or Electronic Device Generated Light (EDGL), such as Light‐Emitting Diodes (LEDs) and digital screens. These sources primarily emit high‐energy visible light (HEVL) within the 400–500 nm range [1, 2, 3]. While the absolute irradiance of EDGL remains significantly lower than that of solar VL, and although current clinical evidence suggests that its emission levels may be insufficient to independently exacerbate pigmentary conditions such as melasma [4], its chronicity and proximity to the integument have raised concerns regarding its cumulative contribution to the total cutaneous oxidative burden [5]. The deleterious effects of VL are dictated by a complex interplay of wavelength, cumulative dose, and individual susceptibility. Unlike UVR, which is primarily absorbed by DNA and proteins, VL interacts with endogenous chromophores such as melanin, flavins, and porphyrins, as well as specialized photoreceptors like opsin‐3 (OPN3). Recent evidence indicates that OPN3 activation in melanocytes triggers a calcium‐dependent signaling cascade that not only stimulates tyrosinase activity but also inhibits autophagy, thereby decreasing melanosome degradation [6]. This mechanism facilitates sustained neomelanogenesis, explaining why clinical Immediate Pigment Darkening (IPD) and Persistent Pigment Darkening (PPD), which result from the oxidation of pre‐existing melanin, are significantly more intense and long‐lasting in skin phototypes III–VI compared to those induced by UVA [1, 3]. At the subcellular level, HEVL promotes mitochondrial dysfunction and overproduction of reactive oxygen species (ROS) through the excitation of respiratory chain components. This oxidative surge activates redox‐sensitive signaling cascades, including mitogen‐activated protein kinases (MAPK/p38) and nuclear factor kappa B (NF‐κβ), which orchestrate the release of pro‐inflammatory cytokines and the upregulation of matrix metalloproteinases (MMPs). Collectively, these processes drive the degradation of the extracellular matrix (ECM), accelerating extrinsic aging (photoaging) and exacerbating VL‐sensitive photodermatoses and pigmentary disorders, including solar urticaria, cutaneous porphyrias, post‐inflammatory hyperpigmentation (PIH) and melasma [1, 2, 7, 8]. Furthermore, while VL is not directly genotoxic, it impairs nucleotide excision repair (NER) mechanisms and contributes to the formation of dark cyclobutane pyrimidine dimers (dark CPDs) through melanin‐mediated chemiexcitation [5, 9]. Traditional filters provide limited protection against the visible spectrum, as their regulatory efficacy is largely confined to wavelengths below 370 nm. This “spectral gap” leaves the skin vulnerable to VL‐induced oxidative and pigmentary damage. Although tinted formulations incorporating iron oxides act as effective physical barriers against HEVL, physical blockage alone may be insufficient to manage the oxidative cascade triggered by the fraction of radiation that bypasses such filters [10, 11]. Consequently, achieving “spectral homeostasis” requires the integration of secondary biological defenses, such as natural compounds (polyphenols, vitamins, and algal extracts), which act as potent ROS scavengers and anti‐inflammatory modulators. The incorporation of natural compounds, particularly botanically derived polyphenols, vitamins, and algal extracts, represents a promising frontier in expanding the photoprotective armamentarium. Unlike traditional filters, these agents offer a multi‐targeted approach, acting as potent ROS scavengers, anti‐inflammatory modulators, and genomic stabilizers. However, despite the growing interest in natural photoprotection, current evidence remains fragmented [12, 13, 14]. To address this important gap in the existing literature, this systematic review aims to critically appraise and synthesize the available evidence on the photoprotective effects of natural compounds against VL‐induced skin damage. This review will move beyond a simple descriptive analysis by emphasizing the precise molecular mechanisms of action, evaluating clinical efficacy across various skin phototypes, and identifying the methodological limitations that currently hinder the standardization and integration of natural agents within modern dermatological therapy. Methods The systematic review protocol was prospectively registered in the PROSPERO database (CRD420251116264). This systematic review was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) 2020 guidelines [15]. Although the initial study protocol intended to perform a meta‐analysis, the substantial lack of reported numerical data (such as means, standard deviations, or exact effect sizes) across the included studies precluded a quantitative synthesis. Consequently, a systematic narrative synthesis was performed. To ensure the robustness of this qualitative approach, the methodological quality and risk of bias were rigorously evaluated using specific validated tools tailored to each study design: ROB‐2 for randomized controlled trials, ROBINS‐I for non‐randomized clinical studies, and the OHAT approach for preclinical evidence. During the preparation of this manuscript, the authors used Gemini for text processing and for the generation of the graphical abstract. The authors reviewed and edited the content as needed and take full responsibility for the integrity of the manuscript. These tools were used only as technical aids and are not listed as authors. Data Sources and Search Strategy A systematic literature search was conducted in PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library, without date restrictions from inception to 2025 by reviewers A.R.‐L. and A.Z. The search strategy combined terms related to VL exposure, skin damage, photoprotection, and natural compounds. Manual citation searching related to our topic studies were also performed to identify additional potential studies. The detailed search strategy and selection process are reported in File S1. Research Question and Eligibility Criteria The research question was formulated using the PICOS (Population, Intervention, Comparator, Outcome and Study design) framework, adapted to experimental and clinical evidence [16]. Population Preclinical studies: Human skin–relevant cellular models, including human keratinocytes, fibroblasts, melanocytes, reconstructed human epidermis, and human skin explants exposed to VL, HEV/blue light (BL), and/or VL + UVA1. Preclinical studies: Human skin–relevant cellular models, including human keratinocytes, fibroblasts, melanocytes, reconstructed human epidermis, and human skin explants exposed to VL, HEV/blue light (BL), and/or VL + UVA1. Clinical studies: Healthy human volunteers undergoing controlled phototesting with VL, HEV/BL, and/or VL + UVA1. Clinical studies: Healthy human volunteers undergoing controlled phototesting with VL, HEV/BL, and/or VL + UVA1. Interventions Interventions involving natural compounds or formulations containing natural ingredients with proposed photoprotective properties, administered topically or orally. These encompassed botanical extracts, isolated phytochemicals, antioxidant blends, and natural compound–enriched sunscreens. Comparators Comparators included untreated controls (even intra‐subject), placebo or vehicle controls, non‐antioxidant sunscreen formulations, or baseline non‐irradiated conditions. Outcomes Eligible studies must report at least one quantitative or semi‐quantitative outcome relevant to VL‐induced skin responses: Preclinical outcomes: ○Cellular viability and morphology○Oxidative stress markers (e.g., ROS, malondialdehyde (MDA), superoxide dismutase (SOD))○Mitochondrial function and membrane potential○Inflammatory and signaling pathways (e.g., MAPK, p38, Nrf2, OPN3)○Pigmentation‐related outcomes (melanin synthesis, melanogenic signaling) Preclinical outcomes: ○Cellular viability and morphology○Oxidative stress markers (e.g., ROS, malondialdehyde (MDA), superoxide dismutase (SOD))○Mitochondrial function and membrane potential○Inflammatory and signaling pathways (e.g., MAPK, p38, Nrf2, OPN3)○Pigmentation‐related outcomes (melanin synthesis, melanogenic signaling) ○Cellular viability and morphology Cellular viability and morphology ○Oxidative stress markers (e.g., ROS, malondialdehyde (MDA), superoxide dismutase (SOD)) Oxidative stress markers (e.g., ROS, malondialdehyde (MDA), superoxide dismutase (SOD)) ○Mitochondrial function and membrane potential Mitochondrial function and membrane potential ○Inflammatory and signaling pathways (e.g., MAPK, p38, Nrf2, OPN3) Inflammatory and signaling pathways (e.g., MAPK, p38, Nrf2, OPN3) ○Pigmentation‐related outcomes (melanin synthesis, melanogenic signaling) Pigmentation‐related outcomes (melanin synthesis, melanogenic signaling) Clinical outcomes: ○Colorimetric parameters (L*, a*, b*, Δa, ΔL*, ITA°, ΔITA, ΔE)○Diffuse reflectance spectroscopy (DRS) parameters (erythema, melanin content, AUC 400–700 nm)○Validated clinical grading scales (e.g., Investigator's Global Assessment for erythema and pigmentation) Clinical outcomes: ○Colorimetric parameters (L*, a*, b*, Δa, ΔL*, ITA°, ΔITA, ΔE)○Diffuse reflectance spectroscopy (DRS) parameters (erythema, melanin content, AUC 400–700 nm)○Validated clinical grading scales (e.g., Investigator's Global Assessment for erythema and pigmentation) ○Colorimetric parameters (L*, a*, b*, Δa, ΔL*, ITA°, ΔITA, ΔE) Colorimetric parameters (L*, a*, b*, Δa, ΔL*, ITA°, ΔITA, ΔE) ○Diffuse reflectance spectroscopy (DRS) parameters (erythema, melanin content, AUC 400–700 nm) Diffuse reflectance spectroscopy (DRS) parameters (erythema, melanin content, AUC 400–700 nm) ○Validated clinical grading scales (e.g., Investigator's Global Assessment for erythema and pigmentation) Validated clinical grading scales (e.g., Investigator's Global Assessment for erythema and pigmentation) Study Design Only interventional studies were included, comprising controlled in vitro/ex vivo experiments and controlled clinical phototesting trials. Exclusion Criteria Studies were excluded based on the following criteria: Studies exclusively conducted in animal models without direct relevance to human skin photoprotection. Studies exclusively conducted in animal models without direct relevance to human skin photoprotection. Studies that only focus on plant biology, phytochemical biosynthesis, or callus cultures without evaluating photoprotection in skin‐relevant models. Studies that only focus on plant biology, phytochemical biosynthesis, or callus cultures without evaluating photoprotection in skin‐relevant models. Studies that use non‐cutaneous cell lines (e.g., ocular, neuronal, or cancer models) unrelated to skin photobiology. Studies that use non‐cutaneous cell lines (e.g., ocular, neuronal, or cancer models) unrelated to skin photobiology. Study protocols, theses, dissertations, and conference proceedings. Study protocols, theses, dissertations, and conference proceedings. Studies lacking validated or reproducible outcome measures. Studies lacking validated or reproducible outcome measures. Study Selection Two reviewers (A.R.‐L. and A.Z.) independently evaluated all retrieved records for eligibility. In the initial screening phase, titles and abstracts were reviewed to identify potentially relevant studies, and duplicate records were removed using a structured Microsoft Excel spreadsheet (Microsoft Corp.). Full‐text articles meeting the preliminary inclusion criteria were subsequently imported into Mendeley desktop (version 2.132.1) reference management software (and independently assessed in full by the same two reviewers, A.R.‐L. and A.Z.) meeting the predefined eligibility criteria. Any discrepancies between reviewers at this stage were resolved through discussion and consensus, with arbitration by a third reviewer (S.G.) when necessary. Data Extraction Data were gathered using a standardized and predefined extraction form developed in Microsoft Excel (Microsoft Corp. Redmond, WA, USA). Data extraction was performed independently by two reviewers (A.R.‐L. and A.Z.). Any discrepancies during the process were resolved through discussion and consensus between the two researchers; in cases where agreement could not be reached, a third reviewer (S.G.) acted as an arbitrator to make the final decision. For preclinical studies, extracted data included the cell or tissue model employed, characteristics of the natural compound and its dosing protocol, irradiation spectrum and dosage, intervention and comparison groups and reported outcome measures. These included mechanistic endpoints related to cytotoxicity, DNA damage, oxidative stress responses, inflammatory responses, pigmentation changes, and signaling pathway alterations. For clinical research studies, extracted variables comprised characteristics of the natural compound and dosing regimen details, irradiation protocol parameters (wavelength range, dose, and irradiance), participant demographics (sample size, age, sex, skin phototype, and ethnicity), characteristics of the intervention and comparison groups, and reported clinical outcomes related to erythema, pigmentation, and histological outcomes. When information was incomplete or presented exclusively in graphical format, this limitation was explicitly recorded in the extraction table. No assumptions were made regarding missing data. Risk of Bias Assessment Risk of bias was independently assessed according to the study design using validated tools. Randomized controlled trials were evaluated using the Cochrane Risk of Bias tool version 2 (ROB‐2), which considers bias arising from the randomization process, deviations from intended interventions, missing outcome data, outcome measurement, and selective reporting. Non‐randomized clinical studies were assessed using the Risk Of Bias In Non‐Randomized Studies‐of Interventions (ROBINS‐I) tool, covering bias due to confounding, participant selection, intervention classification, deviations from intended interventions, missing data, outcome measurement, and selective reporting. Preclinical in vitro and ex vivo studies were evaluated using the Office of Health Assessment and Translation (OHAT) risk‐of‐bias tool, adapted for experimental laboratory research. This tool addresses randomization, allocation concealment, blinding, confounding, exposure characterization, outcome assessment, incomplete data, selective reporting, conflicts of interest, and other sources of bias, with judgments categorized as definitely low, probably low, probably high, or definitely high risk of bias. Two independent reviewers (JCHR and CGM) examined the risk of bias using the mentioned tools. The percentage of agreement between reviewers was calculated for all the tools. Any discrepancies between reviewers were resolved by consensus. Outcome Harmonization and Data Synthesis Given the substantial heterogeneity observed across included studies with respect to experimental models, irradiation protocols, outcome measures, and reporting formats, results were synthesized using a qualitative narrative approach. Evidence from preclinical and clinical studies was analyzed and reported separately and summarized in structured evidence tables. These tables were further stratified according to study type (preclinical versus clinical), light spectrum evaluated (VL, HEV/BL, or combined VL and UVA1 exposure), and the type of natural compound or formulation assessed. A quantitative meta‐analysis was not undertaken due to several methodological constraints, including the frequent absence of numerical outcome data (e.g., means and standard deviations), variability in outcome definitions and assessment time points, and marked heterogeneity in irradiation conditions and intervention formulations across the studies. Certainty of Evidence The certainty of evidence for clinical outcomes was assessed using the GRADE framework. Outcomes related to visible light–induced skin damage, including pigmentation, erythema, and objective biophysical or molecular markers, were considered critical. Randomized controlled trials were initially rated as high certainty and non‐randomized studies as low certainty. Ratings were subsequently modified according to risk of bias, inconsistency, indirectness, imprecision, and publication bias. Risk of bias was informed by ROB‐2 and ROBINS‐I assessments. Inconsistency and indirectness were evaluated considering heterogeneity in irradiation protocols, outcome definitions, and clinical relevance. Imprecision was judged qualitatively based on sample size and robustness of effects, given the absence of meta‐analysis. Publication bias was explored qualitatively due to the limited number of studies. According to GRADE methodology, preclinical in vitro and ex vivo studies were not included in certainty assessments, as the framework is intended for clinical decision‐making based on human evidence; such studies were used only to support biological plausibility. All assessments were performed independently by two reviewers (J‐C.H‐R and C G‐M) with consensus resolution (S.G). Results Study Characteristics Following an initial screening of titles and abstracts, and subsequent full‐text review according to the predefined eligibility criteria, the studies meeting inclusion criteria were retained for qualitative synthesis (Figure 1). The included articles were published between 2008 and 2024 and encompassed both preclinical and clinical investigations evaluating photoprotective strategies against VL, HEV/BL, and/or VL + UVA1 exposure. PRISMA 2020 flow diagram illustrating the study identification, screening, eligibility assessment, and inclusion process for the present systematic review, including records identified through database searches, registers, and other sources. Adapted from [17], under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. Based on the nature of the intervention, the studies were categorized according to the type of natural compound or formulation evaluated. These categories included Polyphenolic compounds, Polysaccharides and amino‐acid derivatives, Vitamins and carotenoids, and Antioxidant blends, algal extracts and others. Regarding study design, the evidence base comprised 15 preclinical studies, which employed human skin cell models, human epidermal equivalents or living skin explants, and murine models, and clinical studies involving controlled phototesting trials in human volunteers. Preclinical and clinical characteristics of the included studies are summarized separately in Table 1 (preclinical studies) and Table 2 (clinical studies), while the overall. TABLE 1Summary of preclinical evidence on the photoprotective effects of natural compounds against VL.StudyCellular modelIngredients/DosesIrradiation/DosesIntervention groups (IG)Comparison groups (CG)Outcome (measures)Main resultsBotta et al. (2008)Human keratinocytes Ectoin (0.025, 0.05, 0.1 mM) (1 h, 37°C)L‐ergothioneine (ERT) (0.1, 0.25, 0.5 mM)Mannitol (0.5, 1, 1.5 mM)Tinted and not‐tinted sunscreens—Photoderm SPF 50 + , tinted Photoderm SPF 50 + , Photoderm Max SPF100 and tinted Photoderm Max SPF100 (2 mg/cm2) UVA/VL: 315–800 nm (8% UVA, 92% VL); doses 5, 10, 15 J/cm2 VL alone: 400–800 nm; doses 5, 10, 15 J/cm2 IG1: Keratinocytes incubated with compounds (ectoin, ERT or mannitol) and exposed to UVA/VL or VLIG2: Keratinocytes incubated with sunscreens and exposed to UVA/VL or VL Non‐irradiated cells (negative control)Non‐irradiated cells treated with MMS (internal DNA‐damage control for comet assay)Irradiated keratinocytes/CHO cells without any protective treatment (positive control)Non‐treated, non‐irradiated keratinocytes (baseline control for protective‐effect assays) Cell viability (WST‐1 assay)DNA damage (comet assay, OTM χ2 values)Photoprotection by ectoin, ERT, mannitol, and sunscreens (comet assay) DNA damage (comet assay): 5 J/cm2: OTM χ2 4.78 ± 0.79 for UVA/VL and 3.78 ± 1.00 for VL (vs 2.90 ± 1.25 for non‐irradiated cells).10 J/cm2: OTM χ2 7.76 ± 1.16 for UVA/VL and 6.34 ± 1.39.15 J/cm2: OTM χ2 9.37 ± 0.31 79 for UVA/VL and 5.91 ± 0.21 for VL. Protective effect of ectoin, ERT, and mannitol: (Values correspond to highest protective dose tested) Ectoin (0.1 mM): VL: OTM 2.37 ± 0.41 → 92.7% protectionUVA/VL: OTM 4.04 ± 0.16 → 68.9% protection L‐ergothioneine (0.5 mM): VL: OTM 2.29 ± 0.19 → 97.9% protectionUVA/VL: OTM 5.15 ± 0.20 → 59.8% protection Mannitol (1.5 mM): VL: OTM 5.18 ± 0.19 → 52% protectionUVA/VL: OTM 6.71 ± 0.29 → 62.7% protection. Protective capacity of sunscreens:Photoderm SPF 50 + :UVA/VL: OTM 3.64 ± 0.23 → 79.9% protectionVL: OTM 2.77 ± 0.24 → 82.8% protection.Photoderm Max SPF100:UVA/VL: OTM 3.14 ± 0.15 → 86.7% protectionVL: OTM 2.47 ± 0.24 → 92.5% protectionTinted Photoderm SPF 50 + :UVA/VL: OTM 2.69 ± 0.22 → 92.6% protectionVL: OTM 2.12 ± 0.08 → 100% protectionTinted Photoderm Max SPF100: UVA/VL: OTM 2.40 ± 0.21 → 97.1% protectionVL: OTM 2.16 ± 0.12 → 100% protection Liebel et al. (2012) Primary human keratinocytes Human epidermal equivalents. Antioxidant blend composed of Feverfew ( Tanacetum parthenium ) extract + Soy ( Glycine soja ) extract + Gamma Tocopherol UVA/UVB sunscreen VL: 65, 130, 180 and 240 J/cm2 IG1: Human skin epidermal equivalents treated with antioxidant blend and exposed to VL IG2: Human skin epidermal equivalents treated with UVA/UVB sunscreen and exposed to VL IG3: Human skin epidermal equivalents treated with antioxidant blend+UVA/UVB sunscreen and exposed to VL CG1: Human primary keratinocytes/equivalents exposed to VL (65–180 J/cm2) (positive control) CG2: Non‐irradiated cells/equivalents (negative control) CG3: Human primary keratinocytes treated with TNFα (positive control) (for EGFR–p42/44 MAPK analysis) ROS production in epidermal equivalentsRelease of proinflammatory cytokines (L‐1α, IL‐6, GM‐CSF, IL‐8, TNFα, MMP‐1 and MMP‐9) in epidermal equivalents (ELISA)EGFR–p42/44 MAPK pathway alteration in human primary keratinocytes (Western blotting)Thymine dimer formation in epidermal equivalents (T–T dimer staining) IG1: Pretreatment with antioxidants similarly reduces ROS, IL‐1α, and MMP‐1 release IG2: Pretreatment with UV sunscreen alone had no protective effects against VL IG3: Pretreatment with antioxidants + UV‐sunscreen reduces ROS, IL‐1a, and MMP‐1 release by 78%, 82%, and 87%, respectively (No numeric values reported) Avola et al. (2019) ‐Human keratinocytes (NCTC 2544) ‐Human dermal fibroblasts Hydroxytyrosol (from Olea europaea fruits) (10, 25, and 50 μg/mL)Blue LED light (LED‐BL):5–85 J/cm2 Keratinocytes and fibroblasts pretreated with hydroxytyrosol (at 10, 25, and 50 μg/mL) for 24 h, followed by LED‐BL exposure CG1: Untreated, non‐irradiated cells (negative control) CG2: Untreated cells exposed to LED‐BL (positive control) Cell viability (MTT assay)ROS intracellular production (H2‐DCFDA assay)DNA damage (8‐hydroxy‐2′‐deoxyguanosine quantification)Expression of collagen I, MMP‐1 and MMP‐12 (RT‐PCR and Western blotting)Expression of PCNA (Western blotting and immunocytochemistry) Cell viability: Hydroxytyrosol showed no cytotoxicity up to 250 μg/mL and preserved cell viability against LED‐BL in both cell types ROS intracellular production: LED‐BL markedly increased ROS levels in keratinocytes and fibroblasts; hydroxytyrosol pretreatment significantly attenuated ROS formation DNA damage: LED‐BL at 15 and 45 J/cm2 strongly increased 8‐OHdG levels; hydroxytyrosol reduced this damage in a dose‐dependent manner Biomarkers' expression: LED‐BL increased MMP‐1 and MMP‐12 and reduced collagen I expression; hydroxytyrosol counteracted these effects in a dose‐dependent manner. LED‐BL also increased PCNA expression, which was inhibited by hydroxytyrosol (No numeric values reported) Zamarrón et al. (2018)Human dermal fibroblastsFernblock(R) (FB) (0.5 and 1 mg/mL)VL: 61.8–247.3 J/cm2 IG1: Cells pretreated with FB (0.5 or 1 mg/mL) for 24 h and subsequently exposed to VL CG1: Untreated, non‐irradiated cells (negative control)CG2: Cells exposed to VL without FB pretreatment (positive control) Cell morphology (microscopy imaging)Cell viability (flow cytometry, FACS)Cell cycle (flow cytometry)ECM proteins expression (MMP‐1, CTSK, FBN1/2 and ELN) (RT‐PCR and/or immunofluorescence) Cell morphology: VL induces cytoplasmic retraction and cellular stretching. Pretreatment with FB delayed the appearance of these morphological alterations Cell viability: FB pretreatment reduced cell death rates to levels comparable to controls Cell cycle: VL alone and FB + VL increased the proportion of cells in S and G2/M phases and decreased G0/G1 phase population ECM proteins expression: MMP1: increased after VL; pretreatment with FB inhibited this increase.CTSK: increased after VL; FB0.5 mg/mL inhibited this increase.FBN1: increased after VL and FB + VLFBN2: increased after VL; FB 0.5 mg/mL inhibited this increase.ELN: increased after VL and FB + VL (No numeric values reported) Freitas et al. (2019)Murine melanoma B16‐F10 melanocytes Apigenin (API)Chrysin (CRI)beta‐carotene (BTC) Dosage: 6.8–100 μg/mL VL: 12–36 J/cm2 (experimental groups irradiated at 36 J/cm2)IG1: B16‐F10 cells induced for melanogenesis (1 mM tyrosine +2.5 mM NH₄Cl), treated with API, CRI, or BTC (6.8–100 μg/mL) for 24 h, followed by VL exposure (36 J/cm2). CG1: B16‐F10 exposed to VL without antioxidant treatment (positive control)B16‐F10 cells treated with antioxidants but not exposed to VL (treatment control) Cell viability (MTT assay)Singlet oxygen detection (spectrophotometry)Membrane photoprotection Cell viability: API at 6.8–100.0 μg/mL suppressed VL‐induced phototoxic effect (16% photoprotection at 6.8 μg/mL)CRI conferred photoprotection ability at 6.8 μg/mL, whereas higher doses decreased viabilityBTC increased cell survival by roughly 10% after VL (at 6.8, 46.4, 68.1 and 100.0 μg (mL)) Singlet oxygen detection: VL‐induced melanin excitation generated singlet oxygen in B16‐F10 cells; all API, CRI and BTC suppressed singlet oxygen formation Membrane photoprotection: API provided significant membrane protection against VL‐induced damage, whereas CRI and BTC did not. (No numeric values reported) Mann et al. (2020)Primary human dermal fibroblastsLicochalcone A (LicA): Solution of 0.1% LicA‐rich licorice extract in DMSOSunscreen (SPF 50+/UVA‐PF 40) containing 0.025% licorice extract (0.005% LicA) VL: 150 mJ/cm2 (> 400 nm, > 450 nm, > 500 nm, and > 585 nm)IG1: Fibroblasts pretreated with LicA (1 μmol/L, 24 h) and subsequently exposed to VLCG: Unirradiated fibroblasts (negative control) ROS production (DCF H2DCFDA assay)Nrf2 activation assay ROS production: VL in the 400 to 450 nm range inducedthe highest ROS levels, with progressively lower ROS generation at longer wavelengths.Pretreatment with LicA at 0.25–2.0 μmol/L markedly reduced VL‐induced ROS formation. Nrf2 activation assay: LicA treatment enhanced Nrf2 activation, producing a five‐fold increase relative to controls (No numeric values reported) Lorrio et al. (2020)Human dermal fibroblasts (HDF) and melanocytes Deschampsia Antarctica extract (EDA, Edafence(R)) (0.1–0.3 mg/mL)BL: 38, 76 and 151 J/cm2 IG1: Fibroblasts pretreated with EDA for 24 h and subjected to BL IG2: Melanocytes pretreated with EDA for 24 h and subjected to BL CG1 (fibroblasts): Fibroblasts not treated with EDA and not exposed to BL (negative control); fibroblasts exposed to BL without EDA pretreatment (positive control) CG2 (melanocytes): Melanocytes not treated with EDA and not exposed to BL (negative control); melanocytes exposed to BL without EDA pretreatment (positive control) Cell viability (MTT assay)ROS production (H2DHFDA assay)Mitochondrial morphology (MitoTracker)Mitochondrial membrane potential (JC‐1 marker)Pigmentation outcomes: p38 melanogenic pathway activation in fibroblasts (Western blotting)intra/extracellular melanin content in melanocytes Cell viability: BL reduced cell viability in both fibroblasts and melanocytesIG1: EDA 0.1 mg/mL significantly increased fibroblasts viability after 38 J/cm2 BL and produced a modest protective effect at 76 J/cm2 IG2: EDA 0.1 mg/mL induced a modest increase of viability in BL‐exposed melanocytes. ROS production: BL increased intracellular ROS in fibroblasts, whereas EDA pretreatment (0.1 mg/mL) reduced BL‐induced ROS levels Mitochondrial morphology: BL altered mitochondria morphology (shorting, round‐shaping, granulation)EDA preserved mitochondrial alterations induced by BL Mitochondrial membrane potential: BL induced membrane hyperpolarization; EDA prevented this BL‐induced alteration Pigmentation: BL activated the p38 melanogenic pathway (in fibroblasts), whereas EDA reduced p38 phosphorylation. BL increased both intracellular and extracellular melanin content in melanocytes; EDA attenuated BL‐induced hyperpigmentation (No numeric values reported) Ayres et al. (2021)Human melanocytes HEMa‐LP French maritime pine bark ( ‐ Pinus pinaster ) extract (PBE) (Pycnogenol) Doses: 0.0316, 0.0100, and 0.00316 mg/mL. VL: 480 J/cm2 ASS (Association of solar‐simulated radiation): UVA/UVB (10 J/cm2) + IR‐A (360 J/cm2) + VL (480 J/cm2) IG: Melanocytes treated with PBE and exposed to VL or ASS after 48 h CG1: Melanocytes not treated with PBE and not exposed to VL/ASS (negative control)Melanocytes only exposed to VL/ASS without PBE pretreatment (positive control) Melanin synthesis (spectrophotometry)Tyrosinase activity (monophenolase activity assay)Endothelin‐1 (ED1) and peroxisome proliferator‐activated receptors (PPAR) α, δ, and γ production (ELISA) Melanin synthesis: VL increased melanin by 5.98% (p < 0.001); ASS increased melanin by 10.56% (p < 0.001). PBE did not prevent VL‐induced melanogenesis but effectively inhibited ASS‐induced increases in melanin production. Tyrosinase activity: PBE reduced tyrosinase activity, with inhibition up to 66.5%. No SD values reported. ED1 production: VL and ASS induced overproduction of ED1 (VL caused an increase of 63.81% and ASS of 57.81%, p < 0.001)PBE pretreatment reduced ED1 overproduction after VL (58.02% reduction at 0.0316 mg/mL; 31.92% at 0.0100 mg/mL) and after ASS (up to 73.05% reduction at 0.0100 mg/mL) (no SD values reported) PPAR α, δ, and γ production: VL did not significantly upregulate PPARs. ASS significantly increased PPAR α, δ, and γ. PBE pretreatment prevented these ASS‐induced increases, reducing levels by 56.60% across all tested concentrations (no numeric SD values reported) Pressi et al. (2021) Human skin keratinocytes (HaCaT).Human living skin explants (SPT II‐III) Melissa officinalis dried powder phytocomplex with high content of rosmarinic acid and polyphenols. Doses: 0.1% for cell cultures0.1% and 0.05% w/v topically applied (2 mg/cm2) for explants BL: 63.75 J/cm2 IG1: HaCaT exposed to H2O2 and treated with Melissa officinalis phytocomplexIG2: Human skin explants treated with Melissa officinalis phytocomplex (daily application for 5 days) and subsequently exposed to BL CG1: Untreated HaCaT cells (negative control).CG2: HaCaT cells treated with N‐acetyl‐L‐cysteine or rutin (positive antioxidant controls).CG3: Unirradiated explants (baseline control) ROS levels in HaCaT keratinocytes (DCF‐DA assay)BL‐induced damage and protective effects in skin explants: ○Cell viability○Nrf2 expression (immunostaining) ROS levels: Melissa Officinalis phythocomplex inhibited H2O2‐induced ROS overproduction Cell viability (skin explants): BL exposure did not alter cell viability, and the phytocomplex also did not induce cytotoxicity (no numeric values reported) Nrf2 expression (skin explants): BL increased activated Nrf2 in the epidermis. Melissa officinalis phytocomplex reduced this activation at 0.05% and fully suppressed it at 0.1% Portillo et al. (2021) Human fibroblasts (HDF)Murine melanocytes (B16‐F10) Fernblock(R) (FB). Doses: 0.1, 0.3, and 0.5 mg/mL (24 h pretreatment) BL: 25–151 J/cm2. IG1 (HDF): Fibroblasts pretreated with FB (0.1–0.5 mg/mL) for 24 h and subsequently exposed to BLIG2 (melanocytes): B16‐F10 melanocytes pretreated with FB (0.1–0.5 mg/mL) for 24 h and exposed to BL; additional DHICA oxidation assay performed with FB and ascorbic acid CG1: Cells without any treatment (negative control).CG2: Cells treated with FB but not‐exposed to BL (treatment control).CG3: Cells exposed to BL without FB pretreatment (positive control)Ascorbic acid as positive antioxidant control in oxidation DHICA test (melanocytes only) HDF: Cell viability (MTT)ROS production (H2DCFDA)Mitochondrial membrane potential (JC‐1)MAPK‐p38 expression (Western blot) Melanocytes: Opsin‐3 expression (RT‐PCR)Intracellular and extracellular melanin production (spectrophotometry)Melanin oxidation (DHICA test) Cell viability in HDF: BL reduced fibroblast viability; FB at 0.5 mg/mL conferred protection even at 76 J/cm2 ROS production in HDF: Pretreatment with FB 0.5 significantly reduced the production of ROS Mitochondrial morphology and membrane potential in HDF: BL induced mitochondrial hyperpolarization (increased in JC‐1 ratio). FB pretreatment restored JC‐1 ratio, preventing hyperpolarization Expression of MAPK‐p38 in HDF: BL increased p38 phosphorilation. FB pretreatment significantly reduced BL‐induced p38 activation Opsin‐3 activation (melanocytes): BL upregulated Opsin‐3 expression; FB pretreatment reduced expression to baseline levels Melanin production (melanocytes): BL induced intra‐ and extracellular hyperpigmentation; FB at 0.5 mg/mL significantly reduced melanin production Melanin oxidation (melanocytes): FB (0.1 and 0.5) demonstrated a protective effect against DHICA‐melanin oxidation, comparable to antioxidant control. (No numeric values reported) Park, Park, et al. (2022)Human dermal fibroblasts (HDFs) Caesalpinia sappan extract (CSE):1–1000 μg/mL for antioxidant evaluation0.313–1.25 μg/mL for skin aging factors evaluation.Brazilin: 0.1 to 1.0 μg/mL BL: 30 J/cm2 for 1 h 7 min IG1: HDFs pretreated with CSE (1–1000 μg/mL for antioxidant evaluation; 0.313–1.25 μg/mL for aging‐factor assays) for 24 h and subsequently exposed to BL IG2: HDFs pretreated with brazilin (0.1–1.0 μg/mL) for 24 h and subsequently exposed to BL CG1 (for IG1‐CSE): HDFs not treated with CSE and not exposed to BL (negative control)HDFs exposed to BL without CSE pretreatment (positive control)HDFs treated with CSE but not exposed to BL (treatment control) CG2 (for IG2—brazilin): HDFs not treated with brazilin and not exposed to BL (negative control)HDFs exposed to BL without brazilin pretreatment (positive control)HDFs treated with brazilin but not exposed to BL (treatment control). Antioxidant ability (SOD‐like activity and DPPH scavenging activity)mRNA expression ofMMP‐1, MMP‐3, collagen type I and collagen type 3 (rt‐PCR)ROS production (DCFDA assay) Antioxidant ability: CSE and brazilin significantly increased SOD‐like activity and DPPH radical scavenging capacity in a dose‐dependent manner, counteracting BL‐induced oxidative stress No numeric values reported. Skin aging factors expression: Pretreatment with CSE or brazilin inhibited BL‐induced upregulation of MMP‐1 and MMP‐3 mRNA. Both treatments also mitigated the BL‐induced reduction in collagen type I and collagen type III mRNA expression No numeric values reported. ROS production: CSE pretreatment attenuated BL‐induced ROS generation in HDFs (No numeric values reported) Park, Kim, et al. (2022)HaCaT human keratinocyte cell line Yellow chaste weed (YCW) (Helichrysum arenarium) extract. Doses: 0.01%, 0.05% and 0.1%Apigenin. Doses: 10, 20, and 30 μMGalangin: 1, 10, and 20 μM *Apigenin and galangin are active components of YWC BL: 13.68 J/cm2 IG1 (YCW): HaCaT cells pretreated with YCW extract (0.01%–0.1%) for 24 h, exposed to BL, and treated again with YCW for 24 hIG2 (Apigenin): HaCaT cells pretreated with apigenin (10–30 μM) for 24 h, exposed to BL, and treated again with apigenin for 24 hIG3 (Galangin): HaCaT cells pretreated with galangin (1–20 μM) for 24 h, exposed to BL, and treated again with galangin for 24 h HaCaT cells without any treatment (negative control)HaCaT cells exposed to BL without pretreatment (positive control)HaCaT cells pretreated with each tested compound (YCW, apigenin, or galangin) but not irradiated (compound‐specific treatment controls) Cell cytotoxicity (CCK‐8)Cell proliferation analysis (CellTiter‐Glo, BrdU ELISA, Click‐iT EdU Imaging)Apoptosis (annexin V flow cytometry)Intracellular calcium influx (Fluo‐4 NW assay)ROS production (DCF‐DA assay)Protein expression: TRPV1, JNK, ERK, p38, FOXO3, Lamin B1, AKT, MST 1/2, nCLU, sCLU, Bax and Bcl‐2 (Western blotting) Cell cytotoxicity: Apigenin showed cytotoxicity at 40 μM; galangin at 30 μM Cell proliferation: YCW extract, apigenin, and galangin increased proliferation in BL‐irradiated HaCaT Apoptosis: BL reduced viable cells to 81.19%; apigenin and galangin increased survival in BL‐irradiated cells. Intracellular calcium influx: BL increased Ca2+ influx via TRPV1 activation. YCW, apigenin, and galangin reduced TRPV1‐mediated Ca2+ influx ROS production: BL induced ROS overproduction. Apigenin and galangin significantly reduced ROS levels Biomarkers' expression: Apigenin and galangin counteracted BL‐induced MAPK signaling changes (↓JNK, ↓ERK/p38 phosphorylation; ↑FoxO3 phosphorylation; ↓MST1/2 phosphorylation; ↑Akt phosphorylation).They also modulated apoptosis/survival markers (↓nCLU, ↑sCLU, ↓Bax, ↑Bcl‐2). (No numeric values reported) Doyeong et al. (2023)Human dermal fibroblasts Curcuma longa L. extract (10–200 μg/mL)BL: 150 J/cm2 IG1— Curcuma longa extract: Fibroblasts treated with C. longa extract (10–200 μg/mL) and subsequently exposed to BL (150 J/cm2). CG1: Fibroblasts without any treatment (negative control)CG2: Fibroblasts exposed to BL without treatment of C. longa L.(positive control for BL damage)CG3: Fibroblasts treated with extract but not irradiated (treatment control) Antioxidant ability (DPPH assay)Reducing power (spectrophotometry)Cytotoxicity of C. longa (MTT assay) Scavenging ability and reducing power: Curcuma longa → RC50 = 40.12 ± 3.07; EC50 → 3087.67 ± 44.78 Cytotoxicity of C. longa : At 200 μg/mL enhanced the viability of fibroblasts by 38%. (No numeric values reported) Lee and Kim (2023)Human skin keratinocytes (HaCaT cells)Anthocyanin antioxidants from cherry fruits ( Prunus serrulata L): Cyanidin‐3‐O‐glucoside (C3OG) (10–200 μM)Cyanidin‐3‐Orutinoside(C3OR) (10–200 μM) BL: 20,000 lx for 1 h IG1—C3OG: HaCaT cells pretreated with C3OG (10–200 μM) for 24 h and exposed to BL IG2—C3OR: HaCaT cells pretreated with C3OR (10–200 μM) for 24 h and exposed to BL CG1: HaCat without any treatment (negative control) CG2: HaCaT exposed to BL without C3OG/C3OR pretreatment (positive control) CG3: HaCaT pretreated with C3OG or C3OR but not irradiated (compound‐specific treatment controls) CG4:NAC (a ROS scavenger) (positive control for ROS production assay) Citotoxicity (MTT assay)ROS production (H2DCFDA assay)MAPK activity (Immunoblotting for FAK, MAPKs, IKKα)Pro‐inflammatory cytokine production (TNF‐α, IL‐6, IL‐8; ELISA)Apoptosis (caspase‐3 activation; cleavage of FAK and PARP; Immunoblotting) Cytotoxicity: C3OG and C3OR reversed BL‐induced cytotoxicity in HaCaT. ROS production: Pre‐treatment with either C3OG or C3OR confered significant protective effect against BL‐induced ROS production in HaCaT. MAPK activity: C3OG or C3OR significantly reduced BL‐induced phosphorylation of FAK, MAPKs, or IKKα.‐ Inflammatory cytokines: C3OG or C3OR significantly inhibited BL‐induced expression of TNF‐α, IL‐6, and IL‐8. Apoptosis: Both compounds decreased cleavage of FAK and PARP by limiting caspase‐3 activation (No numeric values reported) Wu et al. (2024) In vitro: Human skin keratinocytes (HaCaT cells) In vivo: 30 male Kunming mice (5 weeks old) Lycium barbarum polysaccharide (LBP) In vitro: 0.1, 1, and 10 mg/mL; 24 h pretreatment In vivo: Subcutaneous injection for 3 days at 50 mg/mL or 200 mg/mL BL: In vitro: 435–445 nm, 8000 lx, 11.2 W/cm2 In vivo: dorsal skin irradiated 3 days, 8 h/day, 10,000 lx IG1—In vitro:HaCaT cells pretreated with LBP (0.1–10 mg/mL) for 24 h and then exposed to BL (435–445 nm; 8000 lx; 11.2 W/cm2).IG2—In vivo: Mice pretreated with subcutaneous LBP (50 or 200 mg/mL) for 3 days and then BL‐irradiated on dorsal skin CG1‐In vitro controls: HaCaT untreated (CTR)HaCaT exposed to BL onlyHaCaT treated with LBP but not irradiated CG2‐In vivo controls: CTR (normal skin, no BL)BL (blue‐light only)BL + normal saline (vehicle control) Cytotoxicity (MTT assay) In vitro outcomes: Cell morphology (microscopy, imaging)Apoptosis (Annexin V‐FITC kit)ROS production (DFCH‐DA assay)Antioxidant capacity (MDA and SOD levels)Autophagy (LC3B expression) (western blotting and immunofluorescence)Mitochondrial status (JC‐1)Mitophagy (mitochondrial and lisosomal colocalization, immunofluorescence) In vivo outcomes: Skin morphology (H&E and Masson)Antioxidant activity (SOD and MDA expression)Mitophagy (LC3B, PINK‐parkin pathway) In vitro experiments Cytotoxicity: 1 mg/mL LBP pretreatment significantly ameliorates BL‐induced cytotoxicity. (No numeric values reported) In vitro findings: Cell morphology: LBP attenuated BL‐induced morphological damage. Apoptosis: LBP reduced the percentage of apoptotic cells compared with BL alone. ROS: LBP markedly suppressed BL‐induced ROS overproduction. Antioxidant markers: LBP prevented BL‐induced MDA increase and restored SOD activity. Autophagy: LBP reduced BL‐triggered autophagy (↓LC3B/LC3II). Mitochondrial function: LBP restored mitochondrial membrane potential and partially normalized BL‐induced intracellular Ca2+ elevation. Mitophagy: LBP attenuated excessive mitophagy induced by BL. (No numeric values reported) In vivo experiment: Skin morphology: BL caused epidermal and dermal damage; LBP (50–200 mg/mL) improved tissue architecture, with greater protection at 200 mg/mL Collagen structure: LBP prevented BL‐induced collagen fiber disorganization Antioxidant activity: LBP reversed BL‐mediated SOD inhibition and MDA elevation Mitophagy: LBP decreased BL‐induced LC3B expression and reduced activation of the PINK1–Parkin pathway. (No numeric values reported) Summary of preclinical evidence on the photoprotective effects of natural compounds against VL. Ectoin (0.025, 0.05, 0.1 mM) (1 h, 37°C) Ectoin (0.025, 0.05, 0.1 mM) (1 h, 37°C) L‐ergothioneine (ERT) (0.1, 0.25, 0.5 mM) L‐ergothioneine (ERT) (0.1, 0.25, 0.5 mM) Mannitol (0.5, 1, 1.5 mM) Mannitol (0.5, 1, 1.5 mM) Tinted and not‐tinted sunscreens—Photoderm SPF 50 + , tinted Photoderm SPF 50 + , Photoderm Max SPF100 and tinted Photoderm Max SPF100 (2 mg/cm2) Tinted and not‐tinted sunscreens—Photoderm SPF 50 + , tinted Photoderm SPF 50 + , Photoderm Max SPF100 and tinted Photoderm Max SPF100 (2 mg/cm2) UVA/VL: 315–800 nm (8% UVA, 92% VL); doses 5, 10, 15 J/cm2 UVA/VL: 315–800 nm (8% UVA, 92% VL); doses 5, 10, 15 J/cm2 VL alone: 400–800 nm; doses 5, 10, 15 J/cm2 VL alone: 400–800 nm; doses 5, 10, 15 J/cm2 IG1: Keratinocytes incubated with compounds (ectoin, ERT or mannitol) and exposed to UVA/VL or VL IG1: Keratinocytes incubated with compounds (ectoin, ERT or mannitol) and exposed to UVA/VL or VL IG2: Keratinocytes incubated with sunscreens and exposed to UVA/VL or VL IG2: Keratinocytes incubated with sunscreens and exposed to UVA/VL or VL Non‐irradiated cells (negative control) Non‐irradiated cells (negative control) Non‐irradiated cells treated with MMS (internal DNA‐damage control for comet assay) Non‐irradiated cells treated with MMS (internal DNA‐damage control for comet assay) Irradiated keratinocytes/CHO cells without any protective treatment (positive control) Irradiated keratinocytes/CHO cells without any protective treatment (positive control) Non‐treated, non‐irradiated keratinocytes (baseline control for protective‐effect assays) Non‐treated, non‐irradiated keratinocytes (baseline control for protective‐effect assays) Cell viability (WST‐1 assay) Cell viability (WST‐1 assay) DNA damage (comet assay, OTM χ2 values) DNA damage (comet assay, OTM χ2 values) Photoprotection by ectoin, ERT, mannitol, and sunscreens (comet assay) Photoprotection by ectoin, ERT, mannitol, and sunscreens (comet assay) DNA damage (comet assay): 5 J/cm2: OTM χ2 4.78 ± 0.79 for UVA/VL and 3.78 ± 1.00 for VL (vs 2.90 ± 1.25 for non‐irradiated cells).10 J/cm2: OTM χ2 7.76 ± 1.16 for UVA/VL and 6.34 ± 1.39.15 J/cm2: OTM χ2 9.37 ± 0.31 79 for UVA/VL and 5.91 ± 0.21 for VL. 5 J/cm2: OTM χ2 4.78 ± 0.79 for UVA/VL and 3.78 ± 1.00 for VL (vs 2.90 ± 1.25 for non‐irradiated cells). 5 J/cm2: OTM χ2 4.78 ± 0.79 for UVA/VL and 3.78 ± 1.00 for VL (vs 2.90 ± 1.25 for non‐irradiated cells). 10 J/cm2: OTM χ2 7.76 ± 1.16 for UVA/VL and 6.34 ± 1.39. 10 J/cm2: OTM χ2 7.76 ± 1.16 for UVA/VL and 6.34 ± 1.39. 15 J/cm2: OTM χ2 9.37 ± 0.31 79 for UVA/VL and 5.91 ± 0.21 for VL. 15 J/cm2: OTM χ2 9.37 ± 0.31 79 for UVA/VL and 5.91 ± 0.21 for VL. Protective effect of ectoin, ERT, and mannitol: (Values correspond to highest protective dose tested) Ectoin (0.1 mM): VL: OTM 2.37 ± 0.41 → 92.7% protectionUVA/VL: OTM 4.04 ± 0.16 → 68.9% protection VL: OTM 2.37 ± 0.41 → 92.7% protection VL: OTM 2.37 ± 0.41 → 92.7% protection UVA/VL: OTM 4.04 ± 0.16 → 68.9% protection UVA/VL: OTM 4.04 ± 0.16 → 68.9% protection L‐ergothioneine (0.5 mM): VL: OTM 2.29 ± 0.19 → 97.9% protectionUVA/VL: OTM 5.15 ± 0.20 → 59.8% protection VL: OTM 2.29 ± 0.19 → 97.9% protection VL: OTM 2.29 ± 0.19 → 97.9% protection UVA/VL: OTM 5.15 ± 0.20 → 59.8% protection UVA/VL: OTM 5.15 ± 0.20 → 59.8% protection Mannitol (1.5 mM): VL: OTM 5.18 ± 0.19 → 52% protectionUVA/VL: OTM 6.71 ± 0.29 → 62.7% protection. Protective capacity of sunscreens:Photoderm SPF 50 + :UVA/VL: OTM 3.64 ± 0.23 → 79.9% protectionVL: OTM 2.77 ± 0.24 → 82.8% protection.Photoderm Max SPF100:UVA/VL: OTM 3.14 ± 0.15 → 86.7% protectionVL: OTM 2.47 ± 0.24 → 92.5% protectionTinted Photoderm SPF 50 + :UVA/VL: OTM 2.69 ± 0.22 → 92.6% protectionVL: OTM 2.12 ± 0.08 → 100% protectionTinted Photoderm Max SPF100: UVA/VL: OTM 2.40 ± 0.21 → 97.1% protectionVL: OTM 2.16 ± 0.12 → 100% protection VL: OTM 5.18 ± 0.19 → 52% protection VL: OTM 5.18 ± 0.19 → 52% protection UVA/VL: OTM 6.71 ± 0.29 → 62.7% protection. Protective capacity of sunscreens: UVA/VL: OTM 6.71 ± 0.29 → 62.7% protection. Protective capacity of sunscreens: Photoderm SPF 50 + :UVA/VL: OTM 3.64 ± 0.23 → 79.9% protectionVL: OTM 2.77 ± 0.24 → 82.8% protection. Photoderm SPF 50 + : UVA/VL: OTM 3.64 ± 0.23 → 79.9% protection VL: OTM 2.77 ± 0.24 → 82.8% protection. Photoderm Max SPF100:UVA/VL: OTM 3.14 ± 0.15 → 86.7% protectionVL: OTM 2.47 ± 0.24 → 92.5% protection Photoderm Max SPF100: UVA/VL: OTM 3.14 ± 0.15 → 86.7% protection VL: OTM 2.47 ± 0.24 → 92.5% protection Tinted Photoderm SPF 50 + :UVA/VL: OTM 2.69 ± 0.22 → 92.6% protectionVL: OTM 2.12 ± 0.08 → 100% protection Tinted Photoderm SPF 50 + : UVA/VL: OTM 2.69 ± 0.22 → 92.6% protection VL: OTM 2.12 ± 0.08 → 100% protection Tinted Photoderm Max SPF100: UVA/VL: OTM 2.40 ± 0.21 → 97.1% protectionVL: OTM 2.16 ± 0.12 → 100% protection Tinted Photoderm Max SPF100: UVA/VL: OTM 2.40 ± 0.21 → 97.1% protection VL: OTM 2.16 ± 0.12 → 100% protection Primary human keratinocytes Human epidermal equivalents. Antioxidant blend composed of Feverfew ( Tanacetum parthenium ) extract + Soy ( Glycine soja ) extract + Gamma Tocopherol UVA/UVB sunscreen IG1: Human skin epidermal equivalents treated with antioxidant blend and exposed to VL IG2: Human skin epidermal equivalents treated with UVA/UVB sunscreen and exposed to VL IG3: Human skin epidermal equivalents treated with antioxidant blend+UVA/UVB sunscreen and exposed to VL CG1: Human primary keratinocytes/equivalents exposed to VL (65–180 J/cm2) (positive control) CG2: Non‐irradiated cells/equivalents (negative control) CG3: Human primary keratinocytes treated with TNFα (positive control) (for EGFR–p42/44 MAPK analysis) ROS production in epidermal equivalents ROS production in epidermal equivalents Release of proinflammatory cytokines (L‐1α, IL‐6, GM‐CSF, IL‐8, TNFα, MMP‐1 and MMP‐9) in epidermal equivalents (ELISA) Release of proinflammatory cytokines (L‐1α, IL‐6, GM‐CSF, IL‐8, TNFα, MMP‐1 and MMP‐9) in epidermal equivalents (ELISA) EGFR–p42/44 MAPK pathway alteration in human primary keratinocytes (Western blotting) EGFR–p42/44 MAPK pathway alteration in human primary keratinocytes (Western blotting) Thymine dimer formation in epidermal equivalents (T–T dimer staining) Thymine dimer formation in epidermal equivalents (T–T dimer staining) IG1: Pretreatment with antioxidants similarly reduces ROS, IL‐1α, and MMP‐1 release IG2: Pretreatment with UV sunscreen alone had no protective effects against VL IG3: Pretreatment with antioxidants + UV‐sunscreen reduces ROS, IL‐1a, and MMP‐1 release by 78%, 82%, and 87%, respectively (No numeric values reported) ‐Human keratinocytes (NCTC 2544) ‐Human dermal fibroblasts CG1: Untreated, non‐irradiated cells (negative control) CG2: Untreated cells exposed to LED‐BL (positive control) Cell viability (MTT assay) Cell viability (MTT assay) ROS intracellular production (H2‐DCFDA assay) ROS intracellular production (H2‐DCFDA assay) DNA damage (8‐hydroxy‐2′‐deoxyguanosine quantification) DNA damage (8‐hydroxy‐2′‐deoxyguanosine quantification) Expression of collagen I, MMP‐1 and MMP‐12 (RT‐PCR and Western blotting) Expression of collagen I, MMP‐1 and MMP‐12 (RT‐PCR and Western blotting) Expression of PCNA (Western blotting and immunocytochemistry) Expression of PCNA (Western blotting and immunocytochemistry) Cell viability: Hydroxytyrosol showed no cytotoxicity up to 250 μg/mL and preserved cell viability against LED‐BL in both cell types ROS intracellular production: LED‐BL markedly increased ROS levels in keratinocytes and fibroblasts; hydroxytyrosol pretreatment significantly attenuated ROS formation LED‐BL markedly increased ROS levels in keratinocytes and fibroblasts; hydroxytyrosol pretreatment significantly attenuated ROS formation LED‐BL markedly increased ROS levels in keratinocytes and fibroblasts; hydroxytyrosol pretreatment significantly attenuated ROS formation DNA damage: LED‐BL at 15 and 45 J/cm2 strongly increased 8‐OHdG levels; hydroxytyrosol reduced this damage in a dose‐dependent manner LED‐BL at 15 and 45 J/cm2 strongly increased 8‐OHdG levels; hydroxytyrosol reduced this damage in a dose‐dependent manner LED‐BL at 15 and 45 J/cm2 strongly increased 8‐OHdG levels; hydroxytyrosol reduced this damage in a dose‐dependent manner Biomarkers' expression: LED‐BL increased MMP‐1 and MMP‐12 and reduced collagen I expression; hydroxytyrosol counteracted these effects in a dose‐dependent manner. LED‐BL also increased PCNA expression, which was inhibited by hydroxytyrosol LED‐BL increased MMP‐1 and MMP‐12 and reduced collagen I expression; hydroxytyrosol counteracted these effects in a dose‐dependent manner. LED‐BL also increased PCNA expression, which was inhibited by hydroxytyrosol LED‐BL increased MMP‐1 and MMP‐12 and reduced collagen I expression; hydroxytyrosol counteracted these effects in a dose‐dependent manner. LED‐BL also increased PCNA expression, which was inhibited by hydroxytyrosol (No numeric values reported) IG1: Cells pretreated with FB (0.5 or 1 mg/mL) for 24 h and subsequently exposed to VL IG1: Cells pretreated with FB (0.5 or 1 mg/mL) for 24 h and subsequently exposed to VL CG1: Untreated, non‐irradiated cells (negative control) CG1: Untreated, non‐irradiated cells (negative control) CG2: Cells exposed to VL without FB pretreatment (positive control) CG2: Cells exposed to VL without FB pretreatment (positive control) Cell morphology (microscopy imaging) Cell morphology (microscopy imaging) Cell viability (flow cytometry, FACS) Cell viability (flow cytometry, FACS) Cell cycle (flow cytometry) Cell cycle (flow cytometry) ECM proteins expression (MMP‐1, CTSK, FBN1/2 and ELN) (RT‐PCR and/or immunofluorescence) ECM proteins expression (MMP‐1, CTSK, FBN1/2 and ELN) (RT‐PCR and/or immunofluorescence) Cell morphology: VL induces cytoplasmic retraction and cellular stretching. Pretreatment with FB delayed the appearance of these morphological alterations Cell viability: FB pretreatment reduced cell death rates to levels comparable to controls Cell cycle: VL alone and FB + VL increased the proportion of cells in S and G2/M phases and decreased G0/G1 phase population ECM proteins expression: MMP1: increased after VL; pretreatment with FB inhibited this increase.CTSK: increased after VL; FB0.5 mg/mL inhibited this increase.FBN1: increased after VL and FB + VLFBN2: increased after VL; FB 0.5 mg/mL inhibited this increase.ELN: increased after VL and FB + VL MMP1: increased after VL; pretreatment with FB inhibited this increase. MMP1: increased after VL; pretreatment with FB inhibited this increase. CTSK: increased after VL; FB0.5 mg/mL inhibited this increase. CTSK: increased after VL; FB0.5 mg/mL inhibited this increase. FBN1: increased after VL and FB + VL FBN1: increased after VL and FB + VL FBN2: increased after VL; FB 0.5 mg/mL inhibited this increase. FBN2: increased after VL; FB 0.5 mg/mL inhibited this increase. ELN: increased after VL and FB + VL ELN: increased after VL and FB + VL (No numeric values reported) Apigenin (API)Chrysin (CRI)beta‐carotene (BTC) Apigenin (API) Apigenin (API) Chrysin (CRI) Chrysin (CRI) beta‐carotene (BTC) beta‐carotene (BTC) Dosage: 6.8–100 μg/mL CG1: B16‐F10 exposed to VL without antioxidant treatment (positive control) CG1: B16‐F10 exposed to VL without antioxidant treatment (positive control) B16‐F10 cells treated with antioxidants but not exposed to VL (treatment control) B16‐F10 cells treated with antioxidants but not exposed to VL (treatment control) Cell viability (MTT assay) Cell viability (MTT assay) Singlet oxygen detection (spectrophotometry) Singlet oxygen detection (spectrophotometry) Membrane photoprotection Membrane photoprotection Cell viability: API at 6.8–100.0 μg/mL suppressed VL‐induced phototoxic effect (16% photoprotection at 6.8 μg/mL)CRI conferred photoprotection ability at 6.8 μg/mL, whereas higher doses decreased viabilityBTC increased cell survival by roughly 10% after VL (at 6.8, 46.4, 68.1 and 100.0 μg (mL)) API at 6.8–100.0 μg/mL suppressed VL‐induced phototoxic effect (16% photoprotection at 6.8 μg/mL) API at 6.8–100.0 μg/mL suppressed VL‐induced phototoxic effect (16% photoprotection at 6.8 μg/mL) CRI conferred photoprotection ability at 6.8 μg/mL, whereas higher doses decreased viability CRI conferred photoprotection ability at 6.8 μg/mL, whereas higher doses decreased viability BTC increased cell survival by roughly 10% after VL (at 6.8, 46.4, 68.1 and 100.0 μg (mL)) BTC increased cell survival by roughly 10% after VL (at 6.8, 46.4, 68.1 and 100.0 μg (mL)) Singlet oxygen detection: VL‐induced melanin excitation generated singlet oxygen in B16‐F10 cells; all API, CRI and BTC suppressed singlet oxygen formation Membrane photoprotection: API provided significant membrane protection against VL‐induced damage, whereas CRI and BTC did not. (No numeric values reported) Solution of 0.1% LicA‐rich licorice extract in DMSO Solution of 0.1% LicA‐rich licorice extract in DMSO Sunscreen (SPF 50+/UVA‐PF 40) containing 0.025% licorice extract (0.005% LicA) Sunscreen (SPF 50+/UVA‐PF 40) containing 0.025% licorice extract (0.005% LicA) ROS production (DCF H2DCFDA assay) ROS production (DCF H2DCFDA assay) Nrf2 activation assay Nrf2 activation assay ROS production: VL in the 400 to 450 nm range inducedthe highest ROS levels, with progressively lower ROS generation at longer wavelengths.Pretreatment with LicA at 0.25–2.0 μmol/L markedly reduced VL‐induced ROS formation. Nrf2 activation assay: VL in the 400 to 450 nm range inducedthe highest ROS levels, with progressively lower ROS generation at longer wavelengths. VL in the 400 to 450 nm range inducedthe highest ROS levels, with progressively lower ROS generation at longer wavelengths. Pretreatment with LicA at 0.25–2.0 μmol/L markedly reduced VL‐induced ROS formation. Pretreatment with LicA at 0.25–2.0 μmol/L markedly reduced VL‐induced ROS formation. Nrf2 activation assay: Nrf2 activation assay: LicA treatment enhanced Nrf2 activation, producing a five‐fold increase relative to controls (No numeric values reported) IG1: Fibroblasts pretreated with EDA for 24 h and subjected to BL IG2: Melanocytes pretreated with EDA for 24 h and subjected to BL CG1 (fibroblasts): Fibroblasts not treated with EDA and not exposed to BL (negative control); fibroblasts exposed to BL without EDA pretreatment (positive control) CG2 (melanocytes): Melanocytes not treated with EDA and not exposed to BL (negative control); melanocytes exposed to BL without EDA pretreatment (positive control) Cell viability (MTT assay) Cell viability (MTT assay) ROS production (H2DHFDA assay) ROS production (H2DHFDA assay) Mitochondrial morphology (MitoTracker) Mitochondrial morphology (MitoTracker) Mitochondrial membrane potential (JC‐1 marker) Mitochondrial membrane potential (JC‐1 marker) Pigmentation outcomes: Pigmentation outcomes: p38 melanogenic pathway activation in fibroblasts (Western blotting) p38 melanogenic pathway activation in fibroblasts (Western blotting) intra/extracellular melanin content in melanocytes intra/extracellular melanin content in melanocytes Cell viability: BL reduced cell viability in both fibroblasts and melanocytesIG1: EDA 0.1 mg/mL significantly increased fibroblasts viability after 38 J/cm2 BL and produced a modest protective effect at 76 J/cm2 IG2: EDA 0.1 mg/mL induced a modest increase of viability in BL‐exposed melanocytes. BL reduced cell viability in both fibroblasts and melanocytes BL reduced cell viability in both fibroblasts and melanocytes IG1: EDA 0.1 mg/mL significantly increased fibroblasts viability after 38 J/cm2 BL and produced a modest protective effect at 76 J/cm2 IG1: EDA 0.1 mg/mL significantly increased fibroblasts viability after 38 J/cm2 BL and produced a modest protective effect at 76 J/cm2 IG2: EDA 0.1 mg/mL induced a modest increase of viability in BL‐exposed melanocytes. IG2: EDA 0.1 mg/mL induced a modest increase of viability in BL‐exposed melanocytes. ROS production: BL increased intracellular ROS in fibroblasts, whereas EDA pretreatment (0.1 mg/mL) reduced BL‐induced ROS levels BL increased intracellular ROS in fibroblasts, whereas EDA pretreatment (0.1 mg/mL) reduced BL‐induced ROS levels BL increased intracellular ROS in fibroblasts, whereas EDA pretreatment (0.1 mg/mL) reduced BL‐induced ROS levels Mitochondrial morphology: BL altered mitochondria morphology (shorting, round‐shaping, granulation)EDA preserved mitochondrial alterations induced by BL BL altered mitochondria morphology (shorting, round‐shaping, granulation) BL altered mitochondria morphology (shorting, round‐shaping, granulation) EDA preserved mitochondrial alterations induced by BL EDA preserved mitochondrial alterations induced by BL Mitochondrial membrane potential: BL induced membrane hyperpolarization; EDA prevented this BL‐induced alteration BL induced membrane hyperpolarization; EDA prevented this BL‐induced alteration BL induced membrane hyperpolarization; EDA prevented this BL‐induced alteration Pigmentation: BL activated the p38 melanogenic pathway (in fibroblasts), whereas EDA reduced p38 phosphorylation. BL increased both intracellular and extracellular melanin content in melanocytes; EDA attenuated BL‐induced hyperpigmentation BL activated the p38 melanogenic pathway (in fibroblasts), whereas EDA reduced p38 phosphorylation. BL increased both intracellular and extracellular melanin content in melanocytes; EDA attenuated BL‐induced hyperpigmentation BL activated the p38 melanogenic pathway (in fibroblasts), whereas EDA reduced p38 phosphorylation. BL increased both intracellular and extracellular melanin content in melanocytes; EDA attenuated BL‐induced hyperpigmentation (No numeric values reported) French maritime pine bark ( ‐ Pinus pinaster ) extract (PBE) (Pycnogenol) Doses: 0.0316, 0.0100, and 0.00316 mg/mL. VL: 480 J/cm2 VL: 480 J/cm2 ASS (Association of solar‐simulated radiation): UVA/UVB (10 J/cm2) + IR‐A (360 J/cm2) + VL (480 J/cm2) ASS (Association of solar‐simulated radiation): UVA/UVB (10 J/cm2) + IR‐A (360 J/cm2) + VL (480 J/cm2) CG1: Melanocytes not treated with PBE and not exposed to VL/ASS (negative control) CG1: Melanocytes not treated with PBE and not exposed to VL/ASS (negative control) Melanocytes only exposed to VL/ASS without PBE pretreatment (positive control) Melanocytes only exposed to VL/ASS without PBE pretreatment (positive control) Melanin synthesis (spectrophotometry) Melanin synthesis (spectrophotometry) Tyrosinase activity (monophenolase activity assay) Tyrosinase activity (monophenolase activity assay) Endothelin‐1 (ED1) and peroxisome proliferator‐activated receptors (PPAR) α, δ, and γ production (ELISA) Endothelin‐1 (ED1) and peroxisome proliferator‐activated receptors (PPAR) α, δ, and γ production (ELISA) Melanin synthesis: VL increased melanin by 5.98% (p < 0.001); ASS increased melanin by 10.56% (p < 0.001). PBE did not prevent VL‐induced melanogenesis but effectively inhibited ASS‐induced increases in melanin production. Tyrosinase activity: PBE reduced tyrosinase activity, with inhibition up to 66.5%. No SD values reported. ED1 production: VL and ASS induced overproduction of ED1 (VL caused an increase of 63.81% and ASS of 57.81%, p < 0.001)PBE pretreatment reduced ED1 overproduction after VL (58.02% reduction at 0.0316 mg/mL; 31.92% at 0.0100 mg/mL) and after ASS (up to 73.05% reduction at 0.0100 mg/mL) (no SD values reported) VL and ASS induced overproduction of ED1 (VL caused an increase of 63.81% and ASS of 57.81%, p < 0.001) VL and ASS induced overproduction of ED1 (VL caused an increase of 63.81% and ASS of 57.81%, p < 0.001) PBE pretreatment reduced ED1 overproduction after VL (58.02% reduction at 0.0316 mg/mL; 31.92% at 0.0100 mg/mL) and after ASS (up to 73.05% reduction at 0.0100 mg/mL) (no SD values reported) PBE pretreatment reduced ED1 overproduction after VL (58.02% reduction at 0.0316 mg/mL; 31.92% at 0.0100 mg/mL) and after ASS (up to 73.05% reduction at 0.0100 mg/mL) (no SD values reported) PPAR α, δ, and γ production: VL did not significantly upregulate PPARs. ASS significantly increased PPAR α, δ, and γ. PBE pretreatment prevented these ASS‐induced increases, reducing levels by 56.60% across all tested concentrations (no numeric SD values reported) Human skin keratinocytes (HaCaT). Human skin keratinocytes (HaCaT). Human living skin explants (SPT II‐III) Human living skin explants (SPT II‐III) Melissa officinalis dried powder phytocomplex with high content of rosmarinic acid and polyphenols. Doses: 0.1% for cell cultures0.1% and 0.05% w/v topically applied (2 mg/cm2) for explants 0.1% for cell cultures 0.1% for cell cultures 0.1% and 0.05% w/v topically applied (2 mg/cm2) for explants 0.1% and 0.05% w/v topically applied (2 mg/cm2) for explants IG1: HaCaT exposed to H2O2 and treated with Melissa officinalis phytocomplex IG1: HaCaT exposed to H2O2 and treated with Melissa officinalis phytocomplex IG2: Human skin explants treated with Melissa officinalis phytocomplex (daily application for 5 days) and subsequently exposed to BL IG2: Human skin explants treated with Melissa officinalis phytocomplex (daily application for 5 days) and subsequently exposed to BL CG1: Untreated HaCaT cells (negative control). CG1: Untreated HaCaT cells (negative control). CG2: HaCaT cells treated with N‐acetyl‐L‐cysteine or rutin (positive antioxidant controls). CG2: HaCaT cells treated with N‐acetyl‐L‐cysteine or rutin (positive antioxidant controls). CG3: Unirradiated explants (baseline control) CG3: Unirradiated explants (baseline control) ROS levels in HaCaT keratinocytes (DCF‐DA assay) ROS levels in HaCaT keratinocytes (DCF‐DA assay) BL‐induced damage and protective effects in skin explants: ○Cell viability○Nrf2 expression (immunostaining) BL‐induced damage and protective effects in skin explants: ○Cell viability○Nrf2 expression (immunostaining) ○Cell viability Cell viability ○Nrf2 expression (immunostaining) Nrf2 expression (immunostaining) ROS levels: Melissa Officinalis phythocomplex inhibited H2O2‐induced ROS overproduction Melissa Officinalis phythocomplex inhibited H2O2‐induced ROS overproduction Melissa Officinalis phythocomplex inhibited H2O2‐induced ROS overproduction Cell viability (skin explants): BL exposure did not alter cell viability, and the phytocomplex also did not induce cytotoxicity (no numeric values reported) Nrf2 expression (skin explants): BL increased activated Nrf2 in the epidermis. Melissa officinalis phytocomplex reduced this activation at 0.05% and fully suppressed it at 0.1% Human fibroblasts (HDF) Human fibroblasts (HDF) Murine melanocytes (B16‐F10) Murine melanocytes (B16‐F10) Fernblock(R) (FB). Doses: 0.1, 0.3, and 0.5 mg/mL (24 h pretreatment) IG1 (HDF): Fibroblasts pretreated with FB (0.1–0.5 mg/mL) for 24 h and subsequently exposed to BL IG1 (HDF): Fibroblasts pretreated with FB (0.1–0.5 mg/mL) for 24 h and subsequently exposed to BL IG2 (melanocytes): B16‐F10 melanocytes pretreated with FB (0.1–0.5 mg/mL) for 24 h and exposed to BL; additional DHICA oxidation assay performed with FB and ascorbic acid IG2 (melanocytes): B16‐F10 melanocytes pretreated with FB (0.1–0.5 mg/mL) for 24 h and exposed to BL; additional DHICA oxidation assay performed with FB and ascorbic acid CG1: Cells without any treatment (negative control). CG1: Cells without any treatment (negative control). CG2: Cells treated with FB but not‐exposed to BL (treatment control). CG2: Cells treated with FB but not‐exposed to BL (treatment control). CG3: Cells exposed to BL without FB pretreatment (positive control) CG3: Cells exposed to BL without FB pretreatment (positive control) Ascorbic acid as positive antioxidant control in oxidation DHICA test (melanocytes only) Ascorbic acid as positive antioxidant control in oxidation DHICA test (melanocytes only) HDF: Cell viability (MTT)ROS production (H2DCFDA)Mitochondrial membrane potential (JC‐1)MAPK‐p38 expression (Western blot) Cell viability (MTT) Cell viability (MTT) ROS production (H2DCFDA) ROS production (H2DCFDA) Mitochondrial membrane potential (JC‐1) Mitochondrial membrane potential (JC‐1) MAPK‐p38 expression (Western blot) MAPK‐p38 expression (Western blot) Melanocytes: Opsin‐3 expression (RT‐PCR)Intracellular and extracellular melanin production (spectrophotometry)Melanin oxidation (DHICA test) Opsin‐3 expression (RT‐PCR) Opsin‐3 expression (RT‐PCR) Intracellular and extracellular melanin production (spectrophotometry) Intracellular and extracellular melanin production (spectrophotometry) Melanin oxidation (DHICA test) Melanin oxidation (DHICA test) Cell viability in HDF: BL reduced fibroblast viability; FB at 0.5 mg/mL conferred protection even at 76 J/cm2 ROS production in HDF: Pretreatment with FB 0.5 significantly reduced the production of ROS Mitochondrial morphology and membrane potential in HDF: BL induced mitochondrial hyperpolarization (increased in JC‐1 ratio). FB pretreatment restored JC‐1 ratio, preventing hyperpolarization Expression of MAPK‐p38 in HDF: BL increased p38 phosphorilation. FB pretreatment significantly reduced BL‐induced p38 activation Opsin‐3 activation (melanocytes): BL upregulated Opsin‐3 expression; FB pretreatment reduced expression to baseline levels Melanin production (melanocytes): BL induced intra‐ and extracellular hyperpigmentation; FB at 0.5 mg/mL significantly reduced melanin production Melanin oxidation (melanocytes): FB (0.1 and 0.5) demonstrated a protective effect against DHICA‐melanin oxidation, comparable to antioxidant control. (No numeric values reported) Caesalpinia sappan extract (CSE): Caesalpinia sappan extract (CSE): 1–1000 μg/mL for antioxidant evaluation 1–1000 μg/mL for antioxidant evaluation 0.313–1.25 μg/mL for skin aging factors evaluation. 0.313–1.25 μg/mL for skin aging factors evaluation. Brazilin: 0.1 to 1.0 μg/mL Brazilin: 0.1 to 1.0 μg/mL IG1: HDFs pretreated with CSE (1–1000 μg/mL for antioxidant evaluation; 0.313–1.25 μg/mL for aging‐factor assays) for 24 h and subsequently exposed to BL IG2: HDFs pretreated with brazilin (0.1–1.0 μg/mL) for 24 h and subsequently exposed to BL CG1 (for IG1‐CSE): HDFs not treated with CSE and not exposed to BL (negative control)HDFs exposed to BL without CSE pretreatment (positive control)HDFs treated with CSE but not exposed to BL (treatment control) HDFs not treated with CSE and not exposed to BL (negative control) HDFs not treated with CSE and not exposed to BL (negative control) HDFs exposed to BL without CSE pretreatment (positive control) HDFs exposed to BL without CSE pretreatment (positive control) HDFs treated with CSE but not exposed to BL (treatment control) HDFs treated with CSE but not exposed to BL (treatment control) CG2 (for IG2—brazilin): HDFs not treated with brazilin and not exposed to BL (negative control)HDFs exposed to BL without brazilin pretreatment (positive control)HDFs treated with brazilin but not exposed to BL (treatment control). HDFs not treated with brazilin and not exposed to BL (negative control) HDFs not treated with brazilin and not exposed to BL (negative control) HDFs exposed to BL without brazilin pretreatment (positive control) HDFs exposed to BL without brazilin pretreatment (positive control) HDFs treated with brazilin but not exposed to BL (treatment control). HDFs treated with brazilin but not exposed to BL (treatment control). Antioxidant ability (SOD‐like activity and DPPH scavenging activity) Antioxidant ability (SOD‐like activity and DPPH scavenging activity) mRNA expression ofMMP‐1, MMP‐3, collagen type I and collagen type 3 (rt‐PCR) mRNA expression ofMMP‐1, MMP‐3, collagen type I and collagen type 3 (rt‐PCR) ROS production (DCFDA assay) ROS production (DCFDA assay) Antioxidant ability: CSE and brazilin significantly increased SOD‐like activity and DPPH radical scavenging capacity in a dose‐dependent manner, counteracting BL‐induced oxidative stress No numeric values reported. Skin aging factors expression: Pretreatment with CSE or brazilin inhibited BL‐induced upregulation of MMP‐1 and MMP‐3 mRNA. Both treatments also mitigated the BL‐induced reduction in collagen type I and collagen type III mRNA expression No numeric values reported. ROS production: CSE pretreatment attenuated BL‐induced ROS generation in HDFs (No numeric values reported) Yellow chaste weed (YCW) (Helichrysum arenarium) extract. Doses: 0.01%, 0.05% and 0.1%Apigenin. Doses: 10, 20, and 30 μMGalangin: 1, 10, and 20 μM Yellow chaste weed (YCW) (Helichrysum arenarium) extract. Doses: 0.01%, 0.05% and 0.1% Yellow chaste weed (YCW) (Helichrysum arenarium) extract. Doses: 0.01%, 0.05% and 0.1% Apigenin. Doses: 10, 20, and 30 μM Apigenin. Doses: 10, 20, and 30 μM Galangin: 1, 10, and 20 μM Galangin: 1, 10, and 20 μM *Apigenin and galangin are active components of YWC IG1 (YCW): HaCaT cells pretreated with YCW extract (0.01%–0.1%) for 24 h, exposed to BL, and treated again with YCW for 24 hIG2 (Apigenin): HaCaT cells pretreated with apigenin (10–30 μM) for 24 h, exposed to BL, and treated again with apigenin for 24 hIG3 (Galangin): HaCaT cells pretreated with galangin (1–20 μM) for 24 h, exposed to BL, and treated again with galangin for 24 h IG1 (YCW): HaCaT cells pretreated with YCW extract (0.01%–0.1%) for 24 h, exposed to BL, and treated again with YCW for 24 h IG1 (YCW): HaCaT cells pretreated with YCW extract (0.01%–0.1%) for 24 h, exposed to BL, and treated again with YCW for 24 h IG2 (Apigenin): HaCaT cells pretreated with apigenin (10–30 μM) for 24 h, exposed to BL, and treated again with apigenin for 24 h IG2 (Apigenin): HaCaT cells pretreated with apigenin (10–30 μM) for 24 h, exposed to BL, and treated again with apigenin for 24 h IG3 (Galangin): HaCaT cells pretreated with galangin (1–20 μM) for 24 h, exposed to BL, and treated again with galangin for 24 h IG3 (Galangin): HaCaT cells pretreated with galangin (1–20 μM) for 24 h, exposed to BL, and treated again with galangin for 24 h HaCaT cells without any treatment (negative control) HaCaT cells without any treatment (negative control) HaCaT cells exposed to BL without pretreatment (positive control) HaCaT cells exposed to BL without pretreatment (positive control) HaCaT cells pretreated with each tested compound (YCW, apigenin, or galangin) but not irradiated (compound‐specific treatment controls) HaCaT cells pretreated with each tested compound (YCW, apigenin, or galangin) but not irradiated (compound‐specific treatment controls) Cell cytotoxicity (CCK‐8) Cell cytotoxicity (CCK‐8) Cell proliferation analysis (CellTiter‐Glo, BrdU ELISA, Click‐iT EdU Imaging) Cell proliferation analysis (CellTiter‐Glo, BrdU ELISA, Click‐iT EdU Imaging) Apoptosis (annexin V flow cytometry) Apoptosis (annexin V flow cytometry) Intracellular calcium influx (Fluo‐4 NW assay) Intracellular calcium influx (Fluo‐4 NW assay) ROS production (DCF‐DA assay) ROS production (DCF‐DA assay) Protein expression: TRPV1, JNK, ERK, p38, FOXO3, Lamin B1, AKT, MST 1/2, nCLU, sCLU, Bax and Bcl‐2 (Western blotting) Protein expression: TRPV1, JNK, ERK, p38, FOXO3, Lamin B1, AKT, MST 1/2, nCLU, sCLU, Bax and Bcl‐2 (Western blotting) Cell cytotoxicity: Apigenin showed cytotoxicity at 40 μM; galangin at 30 μM Cell proliferation: YCW extract, apigenin, and galangin increased proliferation in BL‐irradiated HaCaT Apoptosis: BL reduced viable cells to 81.19%; apigenin and galangin increased survival in BL‐irradiated cells. Intracellular calcium influx: BL increased Ca2+ influx via TRPV1 activation. YCW, apigenin, and galangin reduced TRPV1‐mediated Ca2+ influx ROS production: BL induced ROS overproduction. Apigenin and galangin significantly reduced ROS levels Biomarkers' expression: Apigenin and galangin counteracted BL‐induced MAPK signaling changes (↓JNK, ↓ERK/p38 phosphorylation; ↑FoxO3 phosphorylation; ↓MST1/2 phosphorylation; ↑Akt phosphorylation).They also modulated apoptosis/survival markers (↓nCLU, ↑sCLU, ↓Bax, ↑Bcl‐2). Apigenin and galangin counteracted BL‐induced MAPK signaling changes (↓JNK, ↓ERK/p38 phosphorylation; ↑FoxO3 phosphorylation; ↓MST1/2 phosphorylation; ↑Akt phosphorylation). Apigenin and galangin counteracted BL‐induced MAPK signaling changes (↓JNK, ↓ERK/p38 phosphorylation; ↑FoxO3 phosphorylation; ↓MST1/2 phosphorylation; ↑Akt phosphorylation). They also modulated apoptosis/survival markers (↓nCLU, ↑sCLU, ↓Bax, ↑Bcl‐2). They also modulated apoptosis/survival markers (↓nCLU, ↑sCLU, ↓Bax, ↑Bcl‐2). (No numeric values reported) IG1— Curcuma longa extract: Fibroblasts treated with C. longa extract (10–200 μg/mL) and subsequently exposed to BL (150 J/cm2). CG1: Fibroblasts without any treatment (negative control) CG1: Fibroblasts without any treatment (negative control) CG2: Fibroblasts exposed to BL without treatment of C. longa L.(positive control for BL damage) CG2: Fibroblasts exposed to BL without treatment of C. longa L.(positive control for BL damage) CG3: Fibroblasts treated with extract but not irradiated (treatment control) CG3: Fibroblasts treated with extract but not irradiated (treatment control) Antioxidant ability (DPPH assay) Antioxidant ability (DPPH assay) Reducing power (spectrophotometry) Reducing power (spectrophotometry) Cytotoxicity of C. longa (MTT assay) Cytotoxicity of C. longa (MTT assay) Scavenging ability and reducing power: Curcuma longa → RC50 = 40.12 ± 3.07; EC50 → 3087.67 ± 44.78 Cytotoxicity of C. longa : At 200 μg/mL enhanced the viability of fibroblasts by 38%. (No numeric values reported) Cyanidin‐3‐O‐glucoside (C3OG) (10–200 μM) Cyanidin‐3‐O‐glucoside (C3OG) (10–200 μM) Cyanidin‐3‐Orutinoside Cyanidin‐3‐Orutinoside (C3OR) (10–200 μM) (C3OR) (10–200 μM) IG1—C3OG: HaCaT cells pretreated with C3OG (10–200 μM) for 24 h and exposed to BL IG2—C3OR: HaCaT cells pretreated with C3OR (10–200 μM) for 24 h and exposed to BL CG1: HaCat without any treatment (negative control) CG2: HaCaT exposed to BL without C3OG/C3OR pretreatment (positive control) CG3: HaCaT pretreated with C3OG or C3OR but not irradiated (compound‐specific treatment controls) CG4:NAC (a ROS scavenger) (positive control for ROS production assay) Citotoxicity (MTT assay) Citotoxicity (MTT assay) ROS production (H2DCFDA assay) ROS production (H2DCFDA assay) MAPK activity (Immunoblotting for FAK, MAPKs, IKKα) MAPK activity (Immunoblotting for FAK, MAPKs, IKKα) Pro‐inflammatory cytokine production (TNF‐α, IL‐6, IL‐8; ELISA) Pro‐inflammatory cytokine production (TNF‐α, IL‐6, IL‐8; ELISA) Apoptosis (caspase‐3 activation; cleavage of FAK and PARP; Immunoblotting) Apoptosis (caspase‐3 activation; cleavage of FAK and PARP; Immunoblotting) Cytotoxicity: C3OG and C3OR reversed BL‐induced cytotoxicity in HaCaT. ROS production: Pre‐treatment with either C3OG or C3OR confered significant protective effect against BL‐induced ROS production in HaCaT. MAPK activity: C3OG or C3OR significantly reduced BL‐induced phosphorylation of FAK, MAPKs, or IKKα.‐ Inflammatory cytokines: C3OG or C3OR significantly inhibited BL‐induced expression of TNF‐α, IL‐6, and IL‐8. Apoptosis: Both compounds decreased cleavage of FAK and PARP by limiting caspase‐3 activation (No numeric values reported) In vitro: Human skin keratinocytes (HaCaT cells) In vivo: 30 male Kunming mice (5 weeks old) In vitro: 0.1, 1, and 10 mg/mL; 24 h pretreatment In vitro: 0.1, 1, and 10 mg/mL; 24 h pretreatment In vivo: Subcutaneous injection for 3 days at 50 mg/mL or 200 mg/mL In vivo: Subcutaneous injection for 3 days at 50 mg/mL or 200 mg/mL BL: In vitro: 435–445 nm, 8000 lx, 11.2 W/cm2 In vivo: dorsal skin irradiated 3 days, 8 h/day, 10,000 lx IG1—In vitro: IG1—In vitro: HaCaT cells pretreated with LBP (0.1–10 mg/mL) for 24 h and then exposed to BL (435–445 nm; 8000 lx; 11.2 W/cm2). HaCaT cells pretreated with LBP (0.1–10 mg/mL) for 24 h and then exposed to BL (435–445 nm; 8000 lx; 11.2 W/cm2). IG2—In vivo: Mice pretreated with subcutaneous LBP (50 or 200 mg/mL) for 3 days and then BL‐irradiated on dorsal skin IG2—In vivo: Mice pretreated with subcutaneous LBP (50 or 200 mg/mL) for 3 days and then BL‐irradiated on dorsal skin CG1‐In vitro controls: HaCaT untreated (CTR)HaCaT exposed to BL onlyHaCaT treated with LBP but not irradiated HaCaT untreated (CTR) HaCaT untreated (CTR) HaCaT exposed to BL only HaCaT exposed to BL only HaCaT treated with LBP but not irradiated HaCaT treated with LBP but not irradiated CG2‐In vivo controls: CTR (normal skin, no BL)BL (blue‐light only)BL + normal saline (vehicle control) CTR (normal skin, no BL) CTR (normal skin, no BL) BL (blue‐light only) BL (blue‐light only) BL + normal saline (vehicle control) BL + normal saline (vehicle control) Cytotoxicity (MTT assay) Cytotoxicity (MTT assay) Cytotoxicity (MTT assay) In vitro outcomes: Cell morphology (microscopy, imaging)Apoptosis (Annexin V‐FITC kit)ROS production (DFCH‐DA assay)Antioxidant capacity (MDA and SOD levels)Autophagy (LC3B expression) (western blotting and immunofluorescence)Mitochondrial status (JC‐1)Mitophagy (mitochondrial and lisosomal colocalization, immunofluorescence) Cell morphology (microscopy, imaging) Cell morphology (microscopy, imaging) Apoptosis (Annexin V‐FITC kit) Apoptosis (Annexin V‐FITC kit) ROS production (DFCH‐DA assay) ROS production (DFCH‐DA assay) Antioxidant capacity (MDA and SOD levels) Antioxidant capacity (MDA and SOD levels) Autophagy (LC3B expression) (western blotting and immunofluorescence) Autophagy (LC3B expression) (western blotting and immunofluorescence) Mitochondrial status (JC‐1) Mitochondrial status (JC‐1) Mitophagy (mitochondrial and lisosomal colocalization, immunofluorescence) Mitophagy (mitochondrial and lisosomal colocalization, immunofluorescence) In vivo outcomes: Skin morphology (H&E and Masson)Antioxidant activity (SOD and MDA expression)Mitophagy (LC3B, PINK‐parkin pathway) Skin morphology (H&E and Masson) Skin morphology (H&E and Masson) Antioxidant activity (SOD and MDA expression) Antioxidant activity (SOD and MDA expression) Mitophagy (LC3B, PINK‐parkin pathway) Mitophagy (LC3B, PINK‐parkin pathway) In vitro experiments Cytotoxicity: 1 mg/mL LBP pretreatment significantly ameliorates BL‐induced cytotoxicity. (No numeric values reported) In vitro findings: Cell morphology: LBP attenuated BL‐induced morphological damage. Apoptosis: LBP reduced the percentage of apoptotic cells compared with BL alone. ROS: LBP markedly suppressed BL‐induced ROS overproduction. Antioxidant markers: LBP prevented BL‐induced MDA increase and restored SOD activity. Autophagy: LBP reduced BL‐triggered autophagy (↓LC3B/LC3II). Mitochondrial function: LBP restored mitochondrial membrane potential and partially normalized BL‐induced intracellular Ca2+ elevation. Mitophagy: LBP attenuated excessive mitophagy induced by BL. (No numeric values reported) In vivo experiment: Skin morphology: BL caused epidermal and dermal damage; LBP (50–200 mg/mL) improved tissue architecture, with greater protection at 200 mg/mL Collagen structure: LBP prevented BL‐induced collagen fiber disorganization Antioxidant activity: LBP reversed BL‐mediated SOD inhibition and MDA elevation Mitophagy: LBP decreased BL‐induced LC3B expression and reduced activation of the PINK1–Parkin pathway. (No numeric values reported) TABLE 2Summary of clinical evidence on the photoprotective effects of natural compounds against visible light.StudyIngredient/DoseIrradiation doseParticipants: N (mean age); sexFitzpatrick skin phototype (SPT); ethnicityIntervention group (IG)Comparison group (CG)Outcome (measures)Main resultsSuitable for meta‐analysisKohli et al. (2017) Polypodium leucotomos extract (PLE), 480 mg oral total (240 mg 2 h before +240 mg 1 h before irradiation)VL (80–480 J/cm2); using a Fiber‐Lite Model 180 with a 150 W EKE lamp with filter GG400/3 mm and 3‐mm hot mirror N = 22 healthy adults (NR); men and women included I–III; (NR) IG: Oral PLE (480 mg) before irradiation; UVB/UVA1/visible light applied to right side of the back on Day 3; assessments on Day 4 (Post‐PLE group)CG: No PLE; identical UVB/UVA1/VL irradiation to left side of the back on Day 1; assessments on Day 2 (Pre‐PLE group) Pigmentation outcomes: IGA of pigmentationColorimetry (b*) Pigmentation: VL did not induce pigmentation in SPT I–III. IGA pigmentation and colorimetry (b*) showed no detectable changes before or after PLE. No numerical VL data were reported, and no protective effect of PLE could be demonstrated under VL exposure a No VL outcomes lack numerical data (no means or SD reported) Mereniuk et al. (2018)Topical Vitamin E cream (vitamin E 20.0% w/w; 114.0 mg α‐tocopherol equivalents/250 IU per gram)VL incremental fluences: 55 J/cm2, 274 J/cm2, 549 J/cm2, and 1098 J/cm2 (irradiance 343 mW/cm2; 99.3% VL) N = 10; (35.5); 63.6% female/36.4% male IV (63.6%) and V (36.4%); Non‐hispanic (72.7%) IG: Topical vitamin E cream applied at 2 mg/cm2 on one side of the back, 24 h and 30 min prior to VL exposure (1 cm2 test sites; randomized intra‐subject)CG: Topical bland emollient (Eucerin cream, no vitamin E) applied at 2 mg/cm2 on the contralateral side, 24 h and 30 min before VL exposure (1 cm2 test sites) Pigmentation outcomes: Visual assessment of lowest fluence inducing pigmentation (Day 7)Colorimetry (ΔL*) at 549 J/cm2 Colorimetry (ΔL*) at 1098 J/cm2 Pigmentation: No significant differences between IG and CG for lowest fluence inducing pigmentation (IG: 480 J/cm2 (SD not reported), CG: 370 J/cm2 (SD not reported) p = 0.182).No differences in pigmentation intensity at 549 J/cm2 (IG: 3.36; CG: 3.73; p = 0.778) or 1098 J/cm2 (IG: 6.85; CG: 6.23; p = 0.585)No differences in ΔL* pigmentation intensity at 1098 J/cm2: IG: 6.85 (SD not reported), CG: 6.23 (SD not reported) (p = 0.585) Vitamin E did not reduce VL–induced pigmentation No Outcomes reported without SD, only means and p‐values Campiche et al. (2020)2 active formulations: Microalgae extract formulation: Base formulation +3% Scenedesmus rubescens dry extract (microalgae extract) (2 mg/cm2 daily)Niacinamide formulation: Base formulation +3% niacinamide (2 mg/cm2 daily) BL irradiation: 60 J/cm2 per day × 4 days (total 240 J/cm2), 450 nm LED, irradiance 54 W/m2 at 9 cm33 healthy subjects; (21–41 years); 100% female III (54.5%) and IV (45.5%) 18 caucasians, 6 asians, 9 mixed Two active topical formulations applied on designated forearm zones: IG1: Microalgae extract formulation IG2: Niacinamide formulation Both formulations were applied daily at 2 mg/cm2 during the conditioning phase (Day‐6 to Day‐1) and recovery phase (Day 4 to Day 28); not applied during irradiation days (Day 0 to Day 3) Active formulations were randomly assigned to inner forearm areas in a double‐blind, intra‐subject randomized design CG: Base cream without active ingredients applied daily at 2 mg/cm2 except irradiation days Assigned to a contralateral forearm zone in the same double‐blind, intra‐subject randomized design Erythema outcomes: Chromameter a* (redness)Hyperspectral imaging: haemoglobin content, oxygen saturation Pigmentation outcomes:Hyperspectral imaging of melanin contentChromameter L*, a*, b*ITA° day 3ΔITA° (change from baseline) Day 3ΔE (overall colour change)Clinical photographic assessment Erythema: BL increased redness (a*) in all groups (p < 0.001). IG2 reduced a* versus CG (p < 0.05); IG1 showed a trend (p = 0.079). Haemoglobin increased post‐irradiation in all groups; IG2 showed a borderline lower increase (p = 0.096). No numeric erythema values were reported. Pigmentation: Melanin content increased in all groups with no significant differences. L* decreased (darkening) in all arms; active groups showed slightly less reduction (no values reported). a* increased; niacinamide reduced a* versus CG (p < 0.05). b* showed no relevant group differences. ΔITA° (Day 3): IG1 = −11.86; IG2 = −13.96; CG = −16.79 (SD not reported); actives showed smaller ITA° decreasesΔE was significantly lower in IG1 versus CG (p < 0.05*) though no numerical values were provided. Photographs showed visibly reduced darkening in IG1 and IG2 versus CG No — Numeric data only reported for ΔITA° (no SD); all other outcomes lack quantitative valuesLyons et al. (2022)Topical antoxidants blend (AO, diethylhexyl syringylidene malonate, vitamin E, ascorbyl palmitate) at 0.5%, 1% and 2% VL + UVA1 irradiation: 480 J/cm2 for SPT I–III; 320 J/cm2 for SPT IV–VI; irradiance ~86 mW/cm2; spectral composition 97.3% VL, 2.0% UVA1, 0.7% IR 20 healthy subjects (NR); 40% female/60% male I‐III (50%); IV–VI (50%) NR IG1: AO blend at 0.5% IG2: AO blend at 1% IG3: AO blend at 2% Applied to separate marked sites on the back; occluded 1 h before exposure; assessments at immediate, 24 h, and Day 7 CG: untreated site and placebo formulation site, treated identically but without active AO Biopsied control site for histology comparison with 2% AO Erythema outcomes: IGAColorimetry (Δa)Diffuse reflectance spectroscopy (DRS) AUC (erythema) Pigmentation outcomes: IGA pigmentationColorimetry (ΔITA)DRS AUC (pigment/darkness) Histology/Molecular outcomes COX‐2 stainingMART‐1 melanocyte countCyclin D1 staining (biopsy at 24 h from 2% AO versus placebo) In SPT I–III: IGA showed trend (ns).2% AO significantly reduced erythema by Δa and DRS AUC immediately post‐irradiation (p < 0.0167); IGA erythema showed a non‐significant trend. Pigmentation changes were minimal In SPT IV–VI: 2% AO significantly reduced immediate pigment darkening (ΔITA p < 0.0167) and showed reduction in delayed tanning at Day 7 (ΔITA p = 0.07) Histology: no significant differences in COX‐2 or MART‐1; Cyclin D1 reduction approached significance only in SPT IV–VI (p = 0.06). AO blends mitigated erythema (SPT I–III) and pigmentation (SPT IV–VI). No No numerical data (means/SD) reported for any erythema, pigmentation, or histology outcomes; multiple interventions; split phototype cohorts Ruvolo et al. (2022) Product A—Control sunscreen (no antioxidants): SPF 50 chemical sunscreen base. Product B—3‐AO sunscreen: SPF 50 + antioxidant blend: 1% diethylhexyl syringylidene malonate;0.25% vitamin E; 0.01% ascorbyl palmitate Product C—5‐AO sunscreen: SPF 50 + enhanced antioxidant blend: 0.5% diethylhexyl syringylidene malonate; 0.25% vitamin E; 0.01% vitamin C; 0.025% licochalcone A; 0.01% glycyrrhetinic acid Product D—Tinted sunscreen: SPF 20 with TiO2 and iron oxides 380 J/cm2 total dose; irradiance ~95 mW/cm2; spectral composition 96.3% VL (400–700 nm), 1.4% UVA1 (340–400 nm), and 2.28% IR (700–1800 nm) using a LS1000 solar simulator N = 10, 9 completed (NR); 100% female IV (33.3%) V (33.3%) VI (33.3%) NR IG1: SPF 50 + 3‐AO blendIG2: SPF 50 + 5‐AO blendIG3: Tinted sunscreen with TiO2 and iron oxides All applied occlusively for 24 h, then re‐applied at 2 mg/cm2 prior to irradiation CG1: untreated irradiated skin (no product) CG2: SPF 50 sunscreen without antioxidants (vehicle control) Erythema outcomes: DRS Δ oxy‐haemoglobinDRS AUC Pigmentation outcomes: (IGA) pigmentation (0–8 scale)DRS (Δ melanin content)DRS AUC (relative dyschromia/darkness) Erythema: IG2 (5‐AO) and IG3 (tinted) showed reduced erythema versus untreated and no‐AO controls CG (p ≈ 0.02–0.07)IG2 and IG3 showed lower erythema AUC versus controls (p < 0.05 at several time points) Pigmentation: IG3 (tinted) showed significantly lower pigmentation than untreated skin (p < 0.05 at all time points)IG2 (5‐AO) showed comparable or better protection than IG3 (p < 0.05 where stated)IG2 had significantly lower Δ melanin at Day 7 compared with no‐AO sunscreen (p < 0.05).IG2 provided the largest reduction in dyschromia, outperforming IG3 and controls (p < 0.05) IG2 (5‐AO) offered the strongest and most consistent protection against VL + UVA1–induced erythema and pigmentation (multiple outcomes p < 0.05). No Means and SD not provided; figures lack numerical axis values; quantitative extraction not possible even via digitization Ezekwe et al. (2024) Product A: SPF60 untinted sunscreen + tocopherol and Cassia alata leaf extract. No iron oxides. Product B: SPF50 tinted sunscreen + zinc oxide 12% + tocopherol and Cassia alata extract +4% iron oxides Product C: SPF50 untinted sunscreen + zinc oxide 12% + tocopherol and Cassia alata extract. No iron oxides Product D: SPF50 tinted sunscreen +11% titanium dioxide + tocopherol and Cassia alata extract +1% iron oxides 320 J/cm2 total dose; irradiance ~80 mW/cm2; spectral composition 95.5% VL (400–700 nm), 3.5% UVA1 (370–400 nm), and 1.0% IR (700–1600 nm) using a LS1000 xenon arc solar simulator12 healthy subjects (32.5 years); 83% female/17% male III (67%) and IV (33%) NR IG‐A: Product A (SPF 60, untinted, no iron oxides)IG‐B: Product B (SPF 50, tinted, 4% iron oxides)IG‐C: Product C (SPF 50, untinted, no iron oxides)IG‐D: Product D (SPF 50, tinted, 1% iron oxides) All products applied at 2 mg/cm2, left for 30 min before irradiation. Duplicate areas for A, B, and untreated control allowed biopsy. CG: Untreated irradiated skin (control site) Erythema outcomes: IGA erythema score (0–5 scale)Colorimetry: Δa*DRS: Δ oxy‐hemoglobinDRS: relative erythema AUC (400–700 nm) Pigmentation outcomes: IGA pigmentation (0–5 scale)Colorimetry: ΔITADRS: relative dyschromia AUC (400–700 nm)DRS: immediate pigment darkening (IPD) visualized on Day 0 Histology/Molecular outcomes COX‐2 stainingMIB1 (cell count)Sox10 (melanocyte count)Fontana‐Masson (melanin pigment intensity) Erythema: IGA erythema: CG = 2.2; lower in IG‐C (1.4) and IG‐D (1.0) (p < 0.05)Δa*: CG = 2.4; lowest in IG‐D (0.7) and IG‐C (1.3) (p < 0.05)Erythema was highest in the CG (1.05). Products C (0.60) and D (0.55) showed the greatest erythema reduction versus control (p < 0.05)CG showed the highest AUC (55). All products reduced AUC, especially D (47) and C (48) versus control (55) Pigmentation: IGA scores: At Day 0, IG‐D (1.0) < CG (2.2) (p < 0.05). At Day 7, all IGs